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ABSTRACT

Circulating lipoproteins are increasingly recognized as innate immune effector
molecules. Severe hypolipidemia, which may occur with trauma or critical illness, is
clinically associated with bacterial pneumonia. Importantly, pneumonia caused by
Staphylococcus aureus is a major cause of morbidity and mortality in both hospital- and
community-acquired pneumonia cases. Here we report that lipoprotein deficiency impairs
early pulmonary innate defense against S. aureus quorum-sensing dependent
pathogenesis. Specifically, apoB levels in the lung early post-infection are significantly
reduced with lipoprotein deficiency, coinciding with impaired host control of S. aureus
agr-signaling and increased agr-dependent morbidity and inflammation. Given that
lipoproteins also inhibit LTA- and LPS-mediated inflammation, these results suggest that
hypolipidemia may broadly impact post-trauma pneumonia susceptibility to both Gram
positive and Gram negative pathogens. Together with previous reports demonstrating that
hyperlipidemia also impairs lung innate defense, these results suggest that maintenance of
normal serum lipoprotein levels is necessary for optimal host innate defense in the lung.
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Chapter 1 – Introduction

Methicillin-resistant Staphylococcus aureus

S. aureus is a Gram-positive bacteria and a human commensal of the skin and the
anterior nares of the upper respiratory tract, with ~20% of the world’s population being
persistently colonized, and an additional ~60% being transiently colonized [1]. The
measure of S. aureus as a successful commensal is clearly indicated by its ubiquitous
prevalence among the human population. In addition, S. aureus is also one of the most
important bacterial pathogens world-wide, based on its prevalence in hospital and
community acquired infections [2-4], and the particular virulence of more recent
emerging antibiotic resistant strains. Since the 1990s, highly virulent community acquired
methicillin-resistant S. aureus (CA-MRSA) strains have become more prevalent worldwide, leading to significantly increased lengths of hospitalization and healthcare costs [5,
6], though the mechanistic reasons for increased virulence in CA-MRSA strains is still
incompletely understood [6]. Importantly, in 2013 MRSA was identified as a “serious
threat” organism by the U.S. Centers for Disease Control (CDC), and was the direct
cause over 11,000 deaths in 2011 [7]. However, this is likely an underestimation of the
true mortality costs of MRSA as cases in which it contributed to death were not included
in this study.
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MRSA Pneumonia

While S. aureus is a leading cause of skin and skin structure infections (SSSI), it
can also lead to more severe life-threatening illnesses, such as bacteremia, endocarditis,
and pneumonia. Pneumonia caused by S. aureus is a major cause of morbidity and
mortality, particularly in cases of post-influenza pneumonia [2]. With the rise in MRSA
cases over the past two decades, along with increases in prolonged ventilator support in
an aging and chronically ill populations, there has been a significant increase in the
number of hospital-acquired pneumonia and ventilator-associated pneumonia cases, with
MRSA accounting for 20-40% of these [4]. A survey of 59 US hospitals in 2005 revealed
that MRSA accounted for a significant portion of community and hospital acquired
pneumonia cases, as well as a significant portion of healthcare and ventilator-associated
pneumonia cases, with S. aureus being the only pathogen independently associated with
mortality [3]. With the rise in pneumonia caused by MRSA, There is a need for an
enhanced understanding of specific host-pathogen interactions during S. aureus infection
in the lung.

The accessory gene regulator, virulence, and pneumonia

The dichotomy of S. aureus as a ubiquitous commensal and a highly virulent
pathogen is, in part, regulated by the accessory gene regulator (agr) operon. The agr
operon encodes a two-component, secretion controlled quorum-sensing (QS) system that
mediates a temporal and cell-density-dependent “switch” from a colonizing to an
2

invasive and virulent phenotype [8] (Figure 1.1). This conserved four gene operon
consists of agrA-D, which is expressed from the P2 promoter [9]. AgrD is a linear peptide
that is cyclized into a mature auto inducing peptide (AIP), and secreted through the
transmembrane protein, AgrB. Secreted AIP signals in an autocrine and paracrine manner
through the transmembrane histidine kinase receptor, AgrC, causing autophosphorylation
of this receptor. AgrC, in turn, phosphorylates the transcription factor AgrA, allowing
AgrA to activate the P2 and P3 promoters. Activation of the P2 promoter drives
expression of the four gene operon, creating a positive feedback loop by increasing agr
gene transcription. AgrA activation of transcription from the divergent P3 promoter
drives expression of RNAIII. RNAIII is a small effector RNA which modulates
expression of hundreds of genes, and turns on an arsenal of virulence factors including a
number of hemolytic toxins, lipases, proteases, and many other exotoxins necessary for S.
aureus invasive infection [8, 10].
Among the most studied agr-regulated virulence factors shown to play a role in
the pathogenesis of S. aureus pneumonia are alpha-hemolysin (Hla), Panton-Valentine
leukocidin (PVL), and the phenol soluble modulins (PSM). Hla is a hemolytic toxin
which is post-transcriptionally regulated by RNAIII [11], and has been shown to be an
important contributor to pathogenesis of S. aureus pneumonia [12, 13]. Through
interaction with the mammalian cell surface receptor ADAM10 [14, 15], Hla forms a
heptameric, barrel shaped, cytolytic pore. This in turn causes a loss of cell membrane
integrity due to potassium efflux, activating the NLRP3 inflammasome, and eventually
leading to cell death [16-18]. PVL is a β-barrel pore forming toxin which is cytotoxic to
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Figure 1.1 - The S. aureus accessory gene regulator (agr).
The agr operon mediates a density dependent phenotype switch from colonizing to
invasive via a positive feedback loop. This in turn increases production of the global
effector RNA, RNAIII, which regulates the expression of an arsenal of virulence factors.
[8].
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leukocytes [19]. Although, PVL has been epidemiologically associated with CA-MRSA
infection world-wide [20], its contribution to invasive disease, specifically necrotizing
pneumonia, has been controversial [20-24]. PSMs are small amphipathic lytic peptides
considered major virulence determinants associated with leukocyte destruction [25], and
whose expression modulates Hla expression [26]. PSMs have been shown to be important
for biofilm structuring and dispersal [27]. Introduction of the PSM expressing locus, psmmec, into non-PSM expressing S. aureus strains promoted biofilm formation [28].
Together, these studies suggest that PSMs may contribute to biofilm infections such as
those associated with catheters and ventilators. Together, these agr-regulated virulence
factors which play a role in S. aureus pneumonia pathogenesis highlight the importance
of understanding host innate immune responses in the lung which target this QS system.

Innate immunity in the lung

The human lung is the largest air to surface exposure site in the human body, with
millions of liters of air ventilated throughout the human lifespan [29], and is thus
constantly exposed to an array of foreign particles and airborne microbial organisms
(Figure 1.2). To avoid constant infection, innate immunity in the lung has become highly
adapted, using physical and chemical barriers in the form of surfactant, the mucocilliary
escalator, antimicrobial peptides (AMP), and lung-specific immune cells.
The lung expresses many AMPs, including lysozyme, α-defensin and β-defensin,
lactoferrin, surfactant proteins A and D, and cathelicidin. As part of the first-line of
defense, AMPs help to directly prevent infection and limit subsequent, potentially
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Figure 1.2 - Innate immunity in the lung.
(1) The lung uses a mucocilliary escalator as a physical barrier that continuously removes
foreign particulates, including potentially harmful microbes. (2) Additionally, lung
epithelial and resident immune cells secrete a myriad of antimicrobial peptides that act to
limit the viability and infectivity of invading pathogens. (3) Resident immune cells
function to phagocytose and remove invading pathogens, and in the case of more severe
infection, regulate inflammation to limit pathology from recruited neutrophils.
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damaging inflammatory responses [30]. However, these AMPs can also have direct
effects on host cell immune cell function. Antimicrobial lung surfactant proteins have
been shown to directly act on lung resident alveolar macrophages (AM) in both a proand anti-inflammatory manner, dependent on the lung microenvironment [31]. For
example, SP-A has also been shown to induce respiratory burst and nitric oxide synthase
(NOS) expression in AMs [32]. Invading pathogens first interact with alveolar epithelial
cells and AMs, which in turn secrete chemokines including IL-8 and RANTES, to recruit
inflammatory cells such as neutrophils, monocytes, and Natural Killer (NK) cells [33-35].
The resident proximity of AMs to the alveolar epithelium and lumen makes them well
suited for lower airway innate immune defense [36]. AMs have been shown to be
essential for phagocytic clearance of a multitude of airway infecting microbes [37, 38],
and the phagocytic abilities of AMs is enhanced during infection and inflammation in the
lung [39]. In addition to their role in removing invading pathogens, AMs and lung
resident dendritic cells, along with regulatory T cells and the lung epithelium, regulate
and minimize potentially damaging inflammation caused by neutrophils [29], via
production of anti-inflammatory cytokines such as IL-10 and TGF-β [40].
While neutrophils are critical to host defense against invading pathogens in the
airway [41, 42], they are also involved in inflammatory pathology in various disease
states [42, 43]. The local inflammatory response during lower airway bacterial infection
is a complex and important process, necessary for host immune defense in the lung
(Figure 1.2). Toll-like receptors (TLR) on neutrophils recognize specific pathogenassociated molecular patterns (PAMP) on invading pathogens, such as LPS and LTA,
leading to eventual activation of the transcription factor NF-κB, which in turn upregulates
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production of pro-inflammatory cytokines and chemokines. Infiltrating neutrophils also
produce proteases, reactive oxygen species (ROS), and reactive nitrogen species (RNS)
which induce necrotic cell death, leading to extensive lung injury [42]. In this way,
neutrophils present a "double-edged sword” component of innate immunity in the lung,
whereby an appropriate neutrophil recruitment response is necessary to limit invasive
infection, but over-recruitment can lead to irreparable damage to the lung. Therefore,
inflammation in the lung must be tightly regulated in order to minimize damage from
invading pathogens, as well as from the host inflammatory response.

Multifunctional role of serum lipoproteins

The term “serum lipoproteins” encompasses a variety of macromolecular lipidprotein complexes which can be divided into different classes based on size, density, and
apolipoprotein associations (Figure 1.3). Among the different serum lipoproteins are
chylomicrons, chylomicron remnants, very low density lipoprotein (VLDL), low density
lipoprotein (LDL), and high density lipoprotein (HDL), which function to store and
transport water-insoluble lipids (cholesterol and triglycerides) throughout the body in a
water-soluble form.
The exogenous lipoprotein metabolism pathway starts when dietary lipids are
incorporated into chylomicrons in the intestine. Processing of chylomicrons by
lipoprotein lipase in peripheral tissues forms chylomicron remnants which are taken up
by the liver. The liver is the major source of the three primary lipoprotein particles
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Figure 1.3 - Differing sizes, apoprotein associations, and functions of serum
lipoproteins.
Chylomicrons are made in the intestine for transporting dietary lipids to tissues. Very low
density lipoprotein (VLDL) is produced in the liver and further metabolized, via
lipoprotein lipase, to low density lipoprotein (LDL) which is the primary source of
cholesterol transported from the liver to the peripheral tissues. HDL is responsible for
reverse cholesterol transport from tissues back to the liver. Adapted from [44].
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produced endogenously, which include VLDL, LDL, and HDL. The liver forms VLDL
which is processed into LDL by lipoprotein lipase in the peripheral tissues. LDL, often
referred to as “bad cholesterol,” contains the highest percentage cholesterol content of all
serum lipoproteins, and is responsible for the majority of cholesterol transport from the
liver to the tissues for uptake via the LDL receptor. In contrast, the reverse cholesterol
transport particle HDL, often referred to as “good cholesterol,” carries cholesterol from
the peripheral tissues back to the liver for excretion, and is anti-atherogenic [45]. In the
case of hyperlipidemia, VLDL and LDL are known to be important contributors to
atherosclerosis and cardiovascular disease [46-49]. In this respect, statins, used to lower
LDL cholesterol levels, have become among the most commonly prescribed drugs worldwide, and have had a significant impact on lowering mortality from cardiovascular
disease [50]. Statins lower serum cholesterol and triglycerides by inhibiting HMG-CoA
reductase, a rate-controlling enzyme in the mevalonate metabolic pathway which controls
cholesterol production [51]. Interestingly, statins have also been associated with
prevention of morbidity and mortality in sepsis [52]. However, this is likely due to their
pleiotropic effects on inflammation and the immune system, including effects occurring
at doses below those required to reduce cholesterol production [53, 54].
In addition to cholesterol transport, recent research also supports the role of
lipoprotein particles as contributors to host innate immunity [55-66]. For example,
apolipoprotein B (apoB) on VLDL and LDL, and apolipoproteins A1 and A2 on HDL,
inhibit lipoteichoic acid (LTA)-mediated inflammatory cytokine release [67]. In mice,
LDL has also been shown to bind lipopolysaccharide (LPS) from Gram-negative bacteria,
reducing its ability to cause endotoxin induced toxicity, morbidity and mortality [68].
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Table 1.1 - Apolipoprotein associations with bacterial infection.

Apolipoprotein

Associated Lipid
Molecule(s)

Association to infection (Host)

Publication(s)

Haplotypes protective against sepsisassociated acute lung injury (Human)

ApoA1

HDL

Anti-microbial against Aeromonas
hydrophila and immunostimulatory to
macrophages (Catfish)

[69-71]

Protective against Trypanosoma brucei
brucei (Human)

ApoA2

HDL

Suppressor of immune activation by LTA
from S. aureus (Human/Mouse immune
cells)

[67]

ApoC1

VLDL

Enhances LPS-induced inflammatory
response (Mouse)

[72]

ApoC2

Chylomicrons
VLDL
HDL

Low levels, a predictive biomarker for
septicemia and necrotizing entercolitis
(Human infants)

[73]

Increased susceptibility to Borrelia
burgdorferi and Borrelia hispanica (ApoE-/mice)

ApoE

Chylomicrons
HDL

Binds to Legionella pneumophilia and may
impede host cell penetration and
intracellular growth, Enhanced
Porphyromonas gingivalis induced
neuronal injury (ApoE-/- mice)

[74-79]
Determinant of innate immune response to
Toll-like receptor ligands in human sepsis
(Human)
Protective against Cryptosporidium parvum
infection (Mouse)
Anti-microbial activity against
Pseudomonas aeruginosa and S. aureus
Inhibits S. aureus quorum-sensing (Mouse)

ApoB-100

VLDL
LDL

Suppressor of immune activation by LTA
from S. aureus (Human/Mouse immune
cells)

[67, 80-82]

Metabolism of apoB plays a role in acute
phase reaction against sepsis (Rat)

ApoB-48

Chylomicrons

Inhibits S. aureus quorum-sensing (Mouse)
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[83]

These and other findings demonstrate that lipoproteins play a role in host innate
immunity against both Gram-positive and Gram-negative pathogens (Table 1).

Dyslipidemia and pulmonary innate defense

Despite the multifunctional role of lipoproteins, most research on the
consequences of dyslipidemia has been largely focused on hyperlipidemia, with these
terms often used interchangeably in the literature, and its impact on cardiovascular
disease [66]. In contrast, few studies have investigated the consequences of hyper- or
hypolipidemia on the host innate response to bacterial infection. Recent findings suggest
that hyperlipidemia results in impaired intrapulmonary host immunity [66, 84], and has
also been shown to impact lipid content of lung surfactants [85]. Alterations in lung
surfactant lipid levels may impair the innate defense function of antimicrobial surfactant
proteins, and have deleterious effects on host defense against bacterial lung infection
[86]. Similarly, hypolipidemia has epidemiologically been associated with increased
mortality [87], as well as with increased susceptibility to bacterial pneumonia [88-90].
The increased infection risk associated with extremes of dyslipidemia suggests that the
role of lipoproteins in host innate immune defense may be under-acknowledged.
However, there is critical gap in knowledge as to how hypolipidemia, as seen during the
acute phase response during severe illness or traumatic injury [91], may play a role in
host innate immune pulmonary defense.
ApoB, the shared structural protein component of chylomicrons, VLDL, and LDL
(Figure 1.3), was previously shown to protect against Staphylococcus aureus skin and
12

skin structure infection (SSSI) through inhibition of the S. aureus QS system [80, 81, 83]
(Figure 1.1). In addition, LDL has been reported to directly bind and inactivate S. aureus
Hla [56], and to a certain extent, the agr-regulated PSMs [65]. Importantly, uptake of
apoB-containing lipoproteins into the lung by the lung capillary endothelium [92], as well
as by carriage through binding to leukocytes [93] has been previously demonstrated.
Although low levels of serum lipoproteins are also associated with increased
susceptibility to bacterial pneumonia [88-90], the contribution of apoB to host defense in
the lung has not been thoroughly investigated.

Concluding remarks and hypothesis

As outlined above, the vast majority of research in dyslipidemia has been focused
on hyperlipidemia, due to its importance in causing cardiovascular disease, but recent
research supports the role of lipoprotein particles as contributors to host innate immunity
against infectious disease. Given the increase in pneumonia caused by MRSA, and the
association between hypolipidemia and susceptibility to bacterial pneumonia [88-90], we
postulated that hypolipidemia, which can result from the acute phase response during
severe illness, may impair host innate immune pulmonary defense (Figure 1.4).
Specifically of interest to the body of research presented herein, apoB quenches S.
aureus QS, thereby limiting the bacteria’s ability to turn on a myriad of virulence factors
necessary for invasive infection. To test the hypothesis that hypolipidemia impairs innate
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Figure 1.4 - Do serum levels of apoB-containing lipoproteins contribute to host innate
pulmonary immune defense against S. aureus infection?
We hypothesized that in a hypolididemic state (right panel), as seen post trauma and
during the acute phase response, lack of apoB-containing lipoproteins in the lung and
airway would lead to lack of control of S. aureus QS during pulmonary infection, as
compared to a normal lipidemic state (left panel).
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pulmonary immune defense against S. aureus agr-mediated infection (Figure 1.4), we
used a sub-lethal model of S. aureus pneumonia in pharmacologically-induced and
genetic mouse models of lipoprotein deficiency. In Chapter 2, we detail optimization of
our chosen S. aureus pneumonia infection model, the importance of consistent
inoculation methodologies for pulmonary infection, procedural considerations and their
effects on consistency of bacterial delivery to the lung. More specifically, we discuss
different infection methods, the effects of intranasal delivery volume on initial infection,
how the choice of anesthetic may effect or confound results, and choosing relevant time
points for our model of infection. In Chapter 3, we show that lipoprotein deficiency
impairs host control of S. aureus QS in the lung, resulting in agr-dependent increases in
pro-inflammatory cytokine production and neutrophil influx in the lung. Furthermore, we
show that apoB inhibits agr-dependent inflammatory cytokine expression by human
alveolar epithelial cells, supporting a role for apoB in limiting QS-dependent virulence
and inflammation during human lung infection. Finally, in Chapter 4, we discuss
considerations for and present data from experimental efforts to use apoB-containing
serum lipoproteins therapeutically in lipoprotein deficient mice infected with S. aureus
pneumonia.
Together, the work reported here advances our understanding of the negative
impact of dyslipidemia on pulmonary host innate defense, and may have broad
implications for hypolipidemia in increased susceptibility to post-trauma pneumonia
caused by both Gram positive and Gram negative pathogens.
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Chapter 2 – Staphylococcus aureus pneumonia mouse model dosing
strategy

Introduction

Mouse models of infection are an important tool for studying infectious agents
and their sequelae. Rapidly reproducing, inbred mouse strains allow for ease of study in
genetically identical backgrounds, facilitating investigation of host-pathogen interactions
via genetics-based approaches. However, using mouse models also comes with many
caveats, including choosing a proper model to elucidate answers to questions about
human disease, or about relevant host-pathogen interactions. Discussed here will be
different accepted practices for using mice as a model organism for studying bacterial
pneumonia and the advantages and pitfalls of different infection methods. We will also
describe the approach we employed to optimize the consistency of S. aureus intranasal
infection looking specifically at the effects of anesthetic on bacterial delivery and S.
aureus infection outcomes, the importance of choosing observational time points for a
mouse model of S. aureus pneumonia relevant to the effects of lipoprotein contributions
to defense against S. aureus in the lung, and intranasal dose delivery volumes.

Inoculum delivery methods for bacterial pneumonia

Aerosol exposure to pathogens mirrors airborne exposure scenarios of infection
[94]. Animals are placed in an enclosed chamber, and aerosolized pathogen is pulled into
16

the chamber. This method has the advantage of requiring no anesthesia, and provides
consistent pathogen deposition into the lung across experimental animal groups [95-97].
Concentrations for appropriate deposition of pathogen into the lungs can be determined
by adjusting exposure time and aerosol flow into the chamber. However, there are many
caveats for aerosol exposure methods. They generally require costly exposure systems,
and in the case of more dangerous pathogens, can create costly containment
considerations. Additionally, fairly large inoculation volumes and concentrations are
required relative to actual pathogen delivery into the lung, creating a limitation on
inoculation level in the lung. Whole-body exposure systems come with the added concern
that off-target inoculation sites will confound experimental results [95], and while noseonly aerosol exposure systems exist, they are more expensive and require additional
costly equipment and time for animal restraint.
Intratracheal infection mouse models of pneumonia mirror lower respiratory tract
infections. Two typical methods for this inoculation method include transtracheal
injection and peroral intubation [94]. Transtracheal injection requires anesthesia followed
by surgical exposure of the trachea, by which a small gauge needle is inserted and the
infection inoculum is delivered directly into the trachea before suturing of the surgical
wound. Peroral intubation avoids potential complications of surgery by delivering
inoculum via blunted needle injection after oral insertion of the needle directly above the
tracheal bifurcation. Whereas both these methods allow for larger bolus dose delivery to
the lung than aerosol administration (discussed above) or intransal infection (discussed
below) [95, 98], the need for prolonged general anesthesia combined with longer delays
between inoculation of individual animals can lead to confounding non-inoculum
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dependent effects. More specifically challenges include anesthesia/aspiration induced
death, and difficulties maintaining consistency of data collection at specific post-infection
time points. The latter is particularly important for short, acute infection models such as
utilized in Chapter 3.
Finally, intranasal infection is another commonly used practice for infecting mice
with a variety of pathogens [13, 99, 100], and may be more relevant in modeling
organisms which infect both the upper and lower respiratory tract. The first intranasal S.
aureus pneumonia model in immunocompetent mice was described by BubeckWardenburg et al. [13]. Since this method was published it has been become standard
practice amongst the S. aureus pneumonia research community [101-103]. In this
approach, mice are anesthetized and the inoculum suspension is introduced into the nares
through aspiration. While this method allows for simple and quick introduction of
pathogens into the mouse airway, it is the most highly variable method for pathogen
delivery to the lung [94], with little control over where pathogens are deposited in the
airway or final inoculum delivered to desired site of infection.

Results and Discussion

Choice of anesthetic impacts intranasal administration of S. aureus
Since intranasal infection requires aspiration by the animal, anesthetic effects on
respiration rates may cause variable levels of inoculum delivery to the lung [104, 105].
Physical effects of particular anesthetics can have profound impact on variation in
inoculum delivery and infection results [94]. In a recent study looking at dosing
18

efficiency of fluorescent F. tularensis via whole body imaging, mice anesthetized with
ketamine/xylazine maintained a steadier breathing pattern than those anesthetized with
short periods of inhaled isoflurane [106]. Despite this, more efficient delivery of
fluorescent F. tularensis to the lungs was seen in mice anesthetized with isoflurane [106].
Additionally, our own observations described below indicate that anesthetic choice can
have profound impacts on weight loss (often used as a measure of morbidity) and
infection outcomes. There are a very limited number of studies observing effects of
different anesthetics on infection outcomes. Interestingly, despite all these variables,
there is a low overall reporting in the literature of actual S. aureus inoculum delivery to
the lung using intranasal infection [106], and though the anesthetic used for infection is
typically reported, the potential impacts of anesthetic choice are not discussed.
In our own studies comparing intranasal inoculation of S. aureus following
parenteral metamine/xylazine or inhaled isoflurane, we found that ketamine/xylazine led
to significant drops in body weight compared to isoflurane (Figure 2.1A). Additionally,
ketamine/xylazine required petroleum jelly to keep the animals’ eyes from drying out
during recovery from anesthesia. Together, this appeared to increase overall morbidity
scoring (consisting of observational measurements of grooming, natural, and provoked
behavior) related to grooming, due to petroleum jelly on and around the eyes, and weight
loss, leading to more moribund mice overall as compared to infection using isoflurane
(Figure 2.1B). We would hypothesize that the longer recovery time from
ketamine/xylazine, compared to isoflurane, leads to significant anesthesia induced weight
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Figure 2.1 - Comparison of weight loss and clinical scores using parenteral
ketamine/xylazine or inhaled isoflurane in mice infected intranasally with S. aureus.
(A) Comparison of weight loss at six hours post intranasal infection with S. aureus, of
vehicle-treated vs. 4-aminopyrizolo[3,4-d]pyrimidine (4APP)-treated mice, anesthetized
for infection using ketamine/xylazine or isoflurane. (B) Comparison of relative morbidity
based on clinical scores at six hours post intranasal infection with S. aureus, of vehicletreated vs. 4APP-treated mice, anesthetized for infection using ketamine/xylazine or
isoflurane.
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loss during recovery and infection. Additionally, observational morbidity measurements
(specifically grooming) seemed to be increased based on lack of grooming in mice that
had petroleum jelly still on and around the eyes (data not shown).

Intranasal dose delivery volumes
Intranasal dose delivery volumes have been shown to have dramatic impacts on
mouse survival during infection. Profound effects related to the deposition site of the
delivered pathogen have also been observed, with lower volumes tending to preferentially
deposit in the upper respiratory tract [104-106]. However, there is a surprising lack of
literature specifically describing the efficiency of delivery into the lung employing
different intranasal dosing volumes for infectious agents. In a study by Miller et al. [84],
they found that delivery volumes between 50 µL to 100 µL were more efficient at
delivery of fluorescent Francisella tularensis into the lung, compared to volumes of 10
µL which resulted in more deposition into the upper respiratory tract. In the case of
intranasal instillation of S. aureus, delivery volumes between 20 µL to 50 µL are
commonly reported [16, 22], however delivery efficiency to the lung at these volumes is
seldom provided [13]. Specifically, the range of commonly reported intranasal bacterial
dosing volumes (2 µL to 100µL), may have dramatically different effects on aspiration of
and general inoculum loss through expulsion by normal breathing.
We observed that delivery volumes above 15 µL required multiple aspiration
steps to limit loss through expulsion by normal breathing, and that splitting a 30 µL
volume delivered in two 15 µL boluses (one to each nare) had less apparent loss of
inhaled volume through expulsion from the airway (data not shown). However, given
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previous findings that volumes above 50 µL showed more efficient bacterial delivery to
the lung during intranasal infection [106], we implemented a “wash down” of the initial
bacterial delivery bolus with two subsequent aspirations of normal saline (15 µL in each
nare), for a total delivery volume of 60 µL. Using this method of intranasal infection, we
found consistent delivery of bacteria to the lung of ~10-20% of initial inoculum (data not
shown).

Choosing observational time points in a mouse model of S. aureus
pneumonia
Though mice are often used as models of infection, due to the ease of use and
wide availability of many potentially clinically relevant genetic knockout mouse models,
one must be careful in selecting an appropriate model for testing a specific hypothesis.
For example, mouse models of S. aureus infection are often criticized because of their
lack of clinical relevance, since S. aureus is not a regular occurring commensal of mice,
and since mice show particular resilience against many of the relevant human virulence
factors [107]. Indeed, the titers needed to achieve significant disease in a mouse model of
S. aureus pneumonia are quite high (2-4 x 108 CFU, [107]). For our specific purposes,
established protocols for intranasal infection with S. aureus, along with two established
models of lowered serum lipoproteins in mice (discussed in detail in Chapter 3), have
allowed us the ability to model infection during the acute phase response of humans, as
related to reductions in serum lipoprotein levels. We found that an increase in a half-log
of S, aureus inoculum titer can make the difference between 24 hour mortality (data not
shown), or an almost three log reduction in CFUs in the lung by 24 hours (Figure 2.2A).
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Figure 2.2 - Clearance of S. aureus from the lung, and weight loss differences at
different time-points of pneumonia.
(A) Differences in CFUs present in the lung at 6 and 24 hours post-infection, of
lipoprotein deficient and control mice, infected intranasally with LAC. (B) Differences in
percentage weight loss at 6 and 24 hours, of lipoprotein deficient and control mice,
infected intranasally with LAC.
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Previous research has also shown that serum lipoprotein levels increase in the
lungs of mice during S. aureus pulmonary infection at 6 hours post-infection [108], as
well as showing increases in inflammatory cytokines (such as IL-1β) in the lung at this
early time point of infection. Given this, and our hypothesis that serum lipoproteins play
a role in innate immunity in the lung during S. aureus infection, a 6 hour model of
infection was chosen as the most relevant time point to assess early control of S. aureus
QS in the lung. Importantly, we observed that at 6 hours post infection, infected mice still
had a substantial portion of the initial infection inoculum present in the lung (Figure
2.2A), and lipoprotein deficient mice showed increased weight-loss compared to controls
(Figure 2.2B). Based on this and previous observations about serum lipoproteins in the
lung and increases in inflammation at this infection time point, we predicted that the
contribution of lipoproteins to pulmonary innate immunity may be best examined at 6
hours post-infection.

Conclusions

Here we emphasize the importance of publishing detailed protocols for pulmonary
infection with bacteria. The described comparative studies resulted in the following
protocol:
1) Isolate 4 mice into an isoflurane chamber and anesthetize using 3.5 L/min of
isoflurane with 2.5 L/min O2 flow.
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2) Remove the first mouse after 5 min in isoflurane chamber, and holding the mouse
at a ~45 ̊ angle with the anterior positioned towards the floor, pipette 15 µl of
saline containing ~2-4 x 108 CFU per 30 µl, onto the left nare.
3) After the mouse has inhaled the first bolus, repeat this for the right nare.
4) Repeat steps 2 and 4 using sterile saline.
5) After the mouse has aspirated the final saline dose, hold the mouse at a ~45 ̊ angle
with the anterior positioned towards the floor, for an additional 1 min.
6) Place mouse prostrate on the floor of housing cage.
7) Repeat this same process for the remaining mice in the isoflurane chamber.
This protocol resulted in a very consistent bacterial delivery to lung (~10-20%) of initial
bacterial suspension titer across all groups and experiments.
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Chapter 3 – Serum Lipoproteins are Critical for Pulmonary Innate
Defense against Staphylococcus aureus Quorum-sensing
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Abstract

Hyperlipidemia has been extensively studied in the context of atherosclerosis,
whereas the potential health consequences of the opposite extreme, hypolipidemia,
remain largely uninvestigated. Circulating lipoproteins are essential carriers of insoluble
lipid molecules and are increasingly recognized as innate immune effectors. Importantly,
severe hypolipidemia, which may occur with trauma or critical illness, is clinically
associated with bacterial pneumonia. To test the hypothesis that circulating lipoproteins
are essential for optimal host innate defense in the lung, we used lipoprotein deficient
mice and a mouse model of Staphylococcus aureus pneumonia in which invasive
infection requires virulence factor expression controlled by the accessory gene regulator
(agr) operon. Activation of agr and subsequent virulence factor expression is inhibited by
apolipoprotein B, the structural protein of low density lipoprotein, which binds and
sequesters the secreted agr-signaling peptide (AIP). Here we report that lipoprotein
deficiency impairs early pulmonary innate defense against S. aureus quorum-sensing
dependent pathogenesis. Specifically, apoB levels in the lung early post-infection are
significantly reduced with lipoprotein deficiency, coinciding with impaired host control
of S. aureus agr-signaling and increased agr-dependent morbidity (weight loss) and
inflammation. Given that lipoproteins also inhibit LTA- and LPS-mediated inflammation,
these results suggest that hypolipidemia may broadly impact post-trauma pneumonia
susceptibility to both Gram positive and Gram negative pathogens. Together with
previous reports demonstrating that hyperlipidemia also impairs lung innate defense,
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these results suggest that maintenance of normal serum lipoprotein levels is necessary for
optimal host innate defense in the lung.
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Introduction

Hyperlipidemia is a clinical syndrome with high circulating levels of cholesterol,
triglycerides and the lipoprotein particles which carry them, including very low and low
density lipoproteins (VLDL, LDL) [87]. Hyperlipidemia is a risk factor for
cardiovascular disease [109, 110], yet serum lipoproteins also contribute to host innate
defense against infection [57, 111]. Interestingly, hyperlipidemia results in impaired
intrapulmonary host immunity [84], suggesting that maintenance of normal circulating
cholesterol and lipoprotein levels is crucial for optimal host innate defense in the lung.
Although severe hypolipidemia, which often accompanies the acute phase response
(APR) following surgery or trauma (reviewed in [112-114]), has been associated with
bacterial pneumonia [88-90], a critical gap in knowledge remains regarding the impact of
extremely low serum lipoprotein levels on host innate defense in the lung.
Staphylococcus aureus, and methicillin-resistant S. aureus (MRSA) in particular,
accounts for 20% to 40% of hospital-acquired pneumonia (HAP) cases in the USA, as
well as a growing number of cases of community-acquired pneumonia (CAP) [115-117].
Invasive pulmonary infection caused by S. aureus requires the expression of virulence
factors controlled by the accessory gene regulator (agr) operon [13, 118-120], which
encodes a two-component quorum-sensing (QS) system for bacterial communication and
coordinated gene expression (reviewed in [8, 121]). QS is facilitated by secretion of a
cyclic autoinducing peptide (AIP), which binds to and activates its cognate surface
receptor AgrC. This in turn leads to expression of over 200 virulence factors [122], many
of which are pre- and post-transcriptionally regulated by a small RNA molecule, called
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RNAIII, produced by transcription from the agr P3 promoter [8, 121]. Importantly,
apolipoprotein B (apoB), the sole protein component of LDL lipoprotein particles, and
not other serum apoproteins or associated lipids, binds and sequesters AIP, thereby
inhibiting agr-signaling and limiting pathogenesis during S. aureus skin infection [80, 83,
123]. However, the impact of apoB deficiency and hypolipidemia on host innate defense
in the lung, and against S. aureus pneumonia in particular, has not been investigated. We
hypothesized that serum lipoproteins would contribute to pulmonary host defense against
S. aureus QS and agr-mediated inflammation.
Here we used a sub-lethal model of S. aureus pneumonia to demonstrate that
severe hypolipidemia impairs the early host innate defense response to lung infection.
Specifically, lipoprotein deficiency impairs host control of S. aureus QS in the lung,
resulting in agr-dependent increases in pulmonary pro-inflammatory cytokine production
and neutrophil influx. Furthermore, apoB inhibits agr-dependent inflammatory cytokine
expression by human alveolar epithelial cells, supporting a role for apoB in limiting QSdependent virulence and inflammation during human lung infection. Given that serum
lipoproteins also limit inflammation via sequestration of lipotechoic acid (LTA) and
lipopolysaccharide (LPS) [124-126], these studies may have broad implications for
hypolipidemia in increased susceptibility to post-trauma pneumonia caused by both Gram
positive and Gram negative pathogens.
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Materials and Methods

Bacterial strains and growth conditions
USA300 LAC and its isogenic agr deletion mutant (USA300 LACΔagr) were provided
by Dr. Frank DeLeo (Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT) and Dr.
Michael Otto (NIAID/NIH, Bethesda, MD), LACΔhla was provided by Dr. Juliane
Bubeck-Wardenburg (University of Chicago, Department of Microbiology, Chicago, IL)
and AH1677 agr::P3-yfp (USA300 LACyfp) was provided by Dr. Alex Horswill
(University of Iowa, Department of Microbiology, Carver College of Medicine). Bacteria
were grown in trypticase soy broth (TSB) and early exponential phase frozen stocks were
prepared as previously described [127]. CFU of frozen stocks were determined by plating
of serial dilutions on blood agar (BD Biosciences, Franklin Lakes, NJ).

Mouse model of S. aureus pneumonia
Animal work was carried out at the AAALAC accredited Animal Research Facility of the
University of New Mexico Health Sciences Center in accordance with recommendations
in the Eighth Edition of The Guide for the Care and Use of Laboratory Animals and the
USA Animal Welfare Act. The protocol was approved by the Institutional Animal Care
and Use Committee (IACUC) of the University of New Mexico. Eight to twelve week
old male mice (C57BL/6, Pcsk9−/− on the B6 x 129 background, and B6 x 129 wild-type)
were purchased from Jackson Laboratories (Bar Harbor, ME). Mice receiving 4aminopyrazole-(3,4-D)pyrimidine (4APP) treatment were injected i.p. with 100 µl of
5.15 mg/ml 4APP (Sigma-Aldrich, St. Louis, MO) prepared as previously described [80,
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123], or buffer control at 48 and 24 hours before infection, as well as at the time of
infection. Reductions in serum cholesterol were determined using Infinity Cholesterol
Liquid Stable Reagent (Thermo Scientific, Middletown, VA) according to manufacturer’s
directions.

The mouse model of S. aureus pneumonia was performed as previously described [13].
Briefly, mice were anesthetized by isoflurane inhalation and 30 µl of sterile saline
containing ~4 x 108 CFU of S. aureus was administered intranasally, followed by an
additional 30 µl of saline alone. Mice were weighed at the time of infection and again
prior to sacrifice. At 6 hours post-infection, mice were sacrificed by CO2 asphyxiation
and blood and tissues collected. For CFU determinations, right lungs were collected in
bead-beating tubes containing 2.3-mm Zirconia/Silica beads (BioSpec Products,
Bartlesville, OK) in 1 ml HBSS- (Life Technologies, Grand Island, NY) with 0.2%
human serum albumin (Sigma-Aldrich, St. Louis, MO), and lung tissue disrupted for 1
min using a Mini-Bead Beater-24 (Biospec). Homogenates were diluted 1:10 in PBS with
0.1% Triton X-100, sonicated, and serial dilutions plated on blood agar (BD Biosciences,
Franklin Lakes, NJ). For agr::P3-YFP promoter activation assays, bacteria from diluted
homogenates were pelleted by centrifugation and fixed for 10 min with 1%
paraformaldehyde containing 25mM CaCl2. Promoter activation was determined by
measuring mean channel fluorescence (MCF) by flow cytometry (Accuri C6, BD Accuri
Cytometers, Ann Arbor, MI). For cytokine and Western blot analyses, lung homogenates
were clarified by centrifugation at 12,500 x g and supernatant was stored at -80 °C until
use as described below. For transcription analyses, left lungs were harvested,
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immediately placed into 1.8 mL of RNAlater (Qiagen, Valencia, CA), and frozen at 80°C.

A549 cell exposure to bacterial supernatant
For A549 assays, bacteria were cultured in TSB (5 mL with 10:1 air to volume ratio) for
6 hours at 37 °C with shaking and with or without 100 nM human LDL (hLDL). Bacteria
were then pelleted by centrifugation and supernatants filter sterilized by passage through
0.2 µm filters, aliquoted, and frozen at -80 °C until use. A549 human alveolar epithelial
cells were grown to 80-90% confluence in 12-well plates in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% heat-inactivated Fetal Bovine Serum (HIFBS) and penicillin/streptomycin. Twenty-four hours prior to use, cell culture medium
was changed to DMEM with 10% human lipoprotein deficient serum with
penicillin/streptomycin. Sterile bacterial supernatants were thawed, diluted to working
concentrations in TSB, and added to A549 cells at a 1:10 dilution in cell culture media.
Post-culture hLDL was added to respective supernatants at 100 nM concentration prior to
addition to A549 cells. Cells were incubated at 37 °C for 4 hours. At 4 hours postexposure, cell culture supernatants were collected and frozen at -80 °C for future
analysis. To collect RNA, cells were immediately lysed with Qiagen RLT buffer with 1%
β-mercaptoethanol and QIAshredder spin columns (Qiagen, Valencia, CA). RNA was
processed using an RNeasy Mini kit, according to the manufacturer’s Animal Cell Spin
protocol (Qiagen, Valencia, CA).

Quantification of cytokines and myeloperoxidase ELISA
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Cytokines were measured in cell culture supernatant or clarified supernatant from mouse
lung homogenates using custom designed Milliplex Cytokine Magnetic kits according to
the manufacturer’s specifications (Millipore, Billerica, MA). Cell culture supernatants
were pooled from identically treated triplicates. Myeloperoxidase was also measured in
clarified supernatants using the Mouse Myeloperoxidase DuoSet ELISA (R&D Systems,
Minneapolis, MN) according to manufacturer’s directions.

Western blot analyses
Clarified lung homogenate supernatants were quick thawed (37°C) and protein
concentrations determined by A280 absorption (Nanodrop 100 Spectrophotometer,
Thermo Fisher Scientific, Wilmington, DE). For apoB Western blots, equivalent amounts
of total protein were separated by SDS-PAGE on 3-8% Tris-Acetate gels (Novex Life
Technologies, Grand Island, NY) prior to transfer to polyvinylidene fluoride (PVDF)
membranes. Membranes were blocked with 5% non-fat milk in TBS (20mM Tris pH 7.5,
150 mM NaCl) containing 0.1% Tween-20 (TBST), then probed with rabbit anti-apoB
antibody (Abcam, Cambridge, MA). Unbound antibody was removed by triplicate 5 min
washes with TBST, and membranes developed using goat anti-rabbit IgG-alkaline
phosphatase-conjugated secondary antibody (KPL, Gaithersburg, MD) and 1-Step
nitroblue tetrazolium (NBT)/5-bromo-4-chloro-3-indolyl-phosphate (BCIP) (Thermo
Scientific).

For Western blot analysis of secreted Hla in bacterial supernatants applied to A549 cells
(above), equivalent amounts of total protein were separated by SDS-PAGE on 4-12%
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Bolt gels (Novex Life Technologies, Grand Island, NY) prior to transfer to
polyvinylidene fluoride (PVDF) membranes and overnight blocking. Membranes were
probed with mouse anti-Hla mAb (Integrated BioTherapeutics, Gaithersburg, MD),
followed by goat anti-rabbit IgG poly-horseradish peroxidase (Thermo Fisher Scientific).
Blots were developed using Thermo Pierce SuperSignal West Pico Chemiluminescent
substrate (Thermo Fisher Scientific). All blots were imaged using a ProteinSimple
FluorChem R instrument and quantified with AlphaView software (Protein Simple, Santa
Clara, CA).

Rabbit erythrocyte lysis assay
Sterile bacterial culture supernatants prepared as described above and used for A549
cytokine induction assays were tested for hemolytic activity as previously described
[128]. Briefly, a 4% solution of rabbit RBCs in PBS was incubated at 37 °C for 1 h with
2-fold serial dilutions of sterile-filtered bacterial supernatant. Lysis was determined by
the A450 of the resulting RBC supernatant. Data were analyzed by nonlinear regression
and are shown as the HA50 which equals 1/ the log of the dilution needed for 50%
complete lysis.

Quantitative RT-PCR
For bacterial RNA isolation, bronchial alveolar lavage fluid (BALF) was collected as
described below but in a 10-fold volume of RNAlater (Qiagen) and frozen at -80 °C for
later processing. After thawing, bacteria were pelleted by centrifugation, RNAlater was
aspirated, and pellets were incubated with 100 µL Tris-EDTA (TE) buffer, with 20
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µL/mL proteinase K (Qiagen) and 20 µg/mL of lysostaphin for 10 min. Thawed lungs
were removed from RNAlater and RNA extracted using Qiazol according to
manufacturer’s directions (Qiagen). RNA isolation from cell culture was performed as
described above. An RNAeasy Mini kit (Qiagen) was used for RNA purification and
cDNA was generated using a high-capacity cDNA RT kit with RNAse inhibitor together
with random hexamer primers (Applied Biosystems, Foster City, CA). Taqman Gene
Expression master mix (Applied Biosystems) and an ABI7000 Real-Timer PCR system
were used for quantitative PCR. Prime Time Predesigned qPCR primers and probes
(Integrated DNA Technologies, Coralville, IA) were used for transcriptional analyses of
mouse hprt, il-1b, mip-2 and il-6, and for human hrpt and il-8. Primers and probes for
quantification of S. aureus 16S, RNAIII and lukS were previously described [129]. Gene
expression was quantified using SDS RQ Manager Version 1.2.2 software (Applied
Biosystems) relative to mouse or human hprt, and S. aureus 16S, as appropriate.

Cell influx analysis of bronchial alveolar lavage fluid
BALF was collected from sacrificed mice by intratracheal lavage, using three sequential
washes (700 µl each) with ice cold Dulbecco’s Phosphate-Buffered Saline (2.67 mM
KCl, 1.47 mM KH2PO4, 138 mM NaCl, 8.1 mM Na2HPO4) (Corning, Corning, NY).
Total cell count and live/dead counts were determined by trypan blue staining using a TC
20 Automated Cell Counter System (Biorad, Hercules, CA). For immunostaining, cells
were centrifuged at 800 x g for 3 min then pelleted cells resuspended in cold PBS with
0.5% BSA and 0.075% sodium azide. Cells were blocked for 30 min with 2% BSA,
followed by a 1-h, 4°C incubation with anti-mouse Ly6G (neutrophils) (BioXCell, West
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Lebanon, NH) conjugated to AlexFluor 488 (Protein labeling kit, Molecular Probes Inc.,
Eugene, OR), anti-mouse CD11c-PE (alveolar macrophages) (Biolegend, San Diego,
CA), or isotype controls. Cells were washed with PBS prior to analysis by flow
cytometry (Accuri C6, BD Accuri Cytometers).

Statistical analyses
All data were analyzed using Prism 5.0 software for Windows (GraphPad Software Inc.,
La Jolla, CA). Parametric data were analyzed using the two-tailed Student’s t-test or
ANOVA with either Dunnett’s post-hoc test or Bonferroni’s multiple comparison test,
and are displayed as the mean ± SEM. Non-parametric data were analyzed by the MannWhitney U test and displayed as the median plus 5th-95th percentiles.
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Results

Lipoprotein deficiency impairs host control of S. aureus QS in the lung
Since lipoproteins are detectable in lungs shortly after intranasal infection with S.
aureus [108] and apoB on LDL binds S. aureus AIP and inhibits agr-activation [80, 83,
123], we predicted that decreased circulating lipoprotein levels would result in impaired
control of S. aureus QS in the lung. To address this, we compared S. aureus agractivation in the lungs of mice with reduced apoB levels versus controls. Given that
APOB deletion is embryonic lethal [130], we used pharmacological treatment with 4aminopyrazole-(3,4-D)pyrimidine (4APP), which inhibits lipoprotein secretion from the
liver [131], and Pcsk9-/- mice, which have reduced circulating LDL levels due to
overexpression of the LDL receptor (LDLR) [132], as models of apoB deficiency. Both
models have an approximately 50% reduction in apoB measured in the serum (Figure
3.1A,B), consistent with those of trauma patients at risk of infection [114]. Using a sublethal challenge model [13], we intranasally infected mice with a reporter strain of the
agr+ clinical isolate LAC, which expresses YFP under the control of the agr::P3
promoter [133]. We measured agr-activation at six hours post-infection, at which time
agr activation is detectable in the lung, as are differences in lung pathogenesis and
bacterial burden between mice infected with agr+ versus ∆agr isolates [118, 134]. As
expected, agr::P3 promoter activation was significantly increased in the lungs of both
4APP-treated and Pcsk9-/- mice compared to controls (Figure 3.2A,D). In addition,
bacteria in BALF collected from LAC infected 4APP-treated mice showed increased
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-/-

Figure 3.1 - 4APP-treated and Pcsk9

mice show similar reductions in serum

cholesterol and apoB.
(A) Quantification of mouse serum cholesterol. (B) Western blot for serum apoB (left)
and apoB quantification by relative band intensity versus control (right). Data shown as
mean ± SEM. N= four mice per group. *, p≤0.05; ***, p≤0.001; ****, p≤0.0001,
Student’s t-test.
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Figure 3.2 - Reduction of circulating lipoproteins increases pulmonary agr-signaling
and weight loss.
Vehicle- or 4APP-treated (A-C, white and gray bars, respectively) and B6 x 129 (WT) or
-/-

Pcsk9 mice (D-F, white and gray bars, respectively) were intranasally infected with
8

agr::P3-YFP LAC or LAC∆agr (4 x 10 CFU) and analyses performed at 6 hours postinfection. (A, D) Flow cytometric quantification of S. aureus agr::P3 promoter activation
in the lungs of lipoprotein deficient mice relative to controls (N=6 mice per group). Data
shown as mean ± SEM. ***, p≤0.001; ****, p≤0.0001, Student’s t-test. (B, E) Weight
loss (g) of infected lipoprotein deficient mice versus controls (N ≥ 8 mice per group from
at least two independent experiments). (C, F) Bacterial burden (Log CFU) in the lung
(N=8 mice per group from two independent experiments). (B-C, E-F) Data shown are
median plus 5th-95th percentiles. ns, not significant; *, p≤0.05, **, p≤0.01, MannWhitney test.
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transcription of agr-regulated RNAIII and lukS-PV, the latter encoding the PantonValentine leukocidin (PVL) (Supplemental Figure 3.1). Furthermore, 4APP-treated and
Pcsk9-/- mice infected with LAC, but not with an isogenic agr mutant (LAC∆agr),
showed increased weight loss, used as a measure of morbidity, compared to vehicletreated and WT controls, respectively (Figure 3.2B,E), suggesting increased virulence in
the lipoprotein deficient mice due to an inability to control agr-signaling. Importantly,
differences in QS and weight loss at this time point were not the result of increased
bacterial burden, as the number of CFUs in the lungs of lipoprotein deficient mice did not
differ from that of controls (Figure 3.2C,F). Therefore, these results suggest that serum
lipoproteins contribute to host control of S. aureus QS-dependent virulence in the lungs
and that this contribution is independent of host control of bacterial burden.

Serum lipoprotein deficiency impacts post-infection lung apoB
concentrations
Increased agr-signaling in the lungs of S. aureus infected lipoprotein deficient
mice (Figure 3.2A,D) suggested that these mice would have decreased apoB present in
the lungs compared to lipoprotein sufficient controls. As suggested, LAC-infected Pcsk9/-

mice showed significantly decreased apoB in the lungs at six hours post-infection

compared to wild-type controls (Figure 3.3A,B). Similarly, compared to vehicle-treated
mice, BALF from mice treated with 4APP and infected with LAC also showed
significant reductions in apoB at the six hour time point (Figure 3.3C,D). In contrast,
differences in apoB levels in BALF from mice infected with LAC∆agr did not reach
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Figure 3.3 - Reduction of serum lipoproteins decreases post-infection apoB levels in
the lung.
(A) Western blot analysis of apoB and (B) relative quantification of apoB versus serum
-/-

control in whole lung homogenates of B6 x 129 (WT) or Pcsk9 mice 6 hours following
intranasal infection with LAC (N=6 mice per group). (C) Western blot analysis and (D)
relative quantification of apoB in BALF from vehicle- or 4APP-treated mice 6 hours
following intranasal infection with LAC or LAC∆agr (N=6 and 3 mice per group,
respectively). Data shown are mean ± SEM. ns, not significant; *, p≤0.05, **, p≤0.01,
Student’s t-test.
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statistical significance. Together, these data suggest that the presence of apoB in the lung
during S. aureus infection, and thus its ability to control agr-signaling in the lung, is
dependent upon circulating lipoprotein concentrations.

Lipoproteins regulate both agr-dependent and agr-independent
induction of pro-inflammatory cytokines in the lung
S. aureus stimulates the release of a variety of cytokines and chemokines in the
lungs of infected mice, including cytokines produced in response to agr-regulated
virulence factors [13, 18, 101, 108, 119, 135, 136]. In particular, expression of the agrregulated virulence factor alpha-hemolysin (Hla), a pore-forming toxin, induces
pulmonary release of the pro-inflammatory cytokine IL-1β [18, 101], suggesting there
would be an agr- and Hla-dependent increase in IL-1β in the lungs of lipoprotein
deficient mice compared to controls. As predicted, 4APP-treated mice infected with
LAC, but not with LAC∆agr or LAC∆hla, had significantly increased pulmonary IL-1β
levels at six hours post-infection compared to vehicle-treated mice (Figure 3.4A),
consistent with increased morbidity (weight loss) relative to vehicle controls only with
LAC infection (Figure 3.2B, 3.4B). Also, as seen for LAC and LAC∆agr infected mice,
bacterial burden did not differ between 4APP- and vehicle-treated mice infected with
LAC∆hla (Figure 3.4C). Interestingly, IL-1β expression was reduced in lipoprotein
deficient mice infected with LAC∆agr (Figure 3.4A), although the mechanism driving
this response remains unclear. Therefore, although Hla expression in lung homogenate of
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Figure 3.4- Lipoproteins limit Hla-dependent pulmonary IL-1β production.
(A) IL-1β levels in whole lung homogenate from vehicle- and 4APP-treated mice (white
and gray bars, respectively) 6 hours following intranasal infection with the indicated
isolate. Data shown are mean ± SEM. ns, not significant; *, p≤0.05, Student’s t-test. (B)
Weight loss (g) of infected lipoprotein deficient mice versus controls (N=8 mice per
group from two independent experiments. (C) Bacterial burden (Log CFU) in the lung.
N=8 mice per group. (B-C) Data shown are median plus 5th-95th percentiles. ns, not
significant, Mann-Whitney test.
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LAC infected mice was below the limit of detection at six hours post-infection (Western
blot data not shown), these results suggest that lipoproteins inhibit agr-dependent Hla
production and associated virulence in the lungs early during S. aureus infection.
In addition to inhibiting agr-signaling, apoB on LDL also binds lipotechoic acid
(LTA) from S. aureus and limits LTA-induced expression of IL-6 [126]. To distinguish
between agr-dependent and agr-independent effects of lipoprotein deficiency on
pulmonary inflammatory cytokine production, we measured lung cytokine levels in WT
and Pcsk9-/- mice intranasally infected with LAC or LAC∆agr. In addition to IL-1β and
IL-6, we measured production of macrophage inflammatory protein 2 (MIP-2), a
neutrophil chemotactic protein, which has also been shown to be driven by agr-regulated
Hla [137]. At six hours post-infection, IL-1β and MIP-2 levels were significantly
increased in the lungs of Pcsk9-/- mice infected with LAC, but not with LAC∆agr (Figure
3.5A,B), consistent with impaired host control of QS in the lungs of lipoprotein deficient
mice. In contrast, compared to WT mice, IL-6 was increased in the lungs of both LAC
and LAC∆agr infected Pcsk9-/- mice (Figure 3.5C), further supporting a role for apoB in
limiting LTA-induced expression of this inflammatory cytokine [126]. Therefore, these
data demonstrate that apoB limits S. aureus-induced inflammatory cytokine production in
the lung in both an agr-dependent and an agr-independent manner.

Lipoproteins regulate agr-dependent neutrophil influx in the lung
Appropriate recruitment of neutrophils during S. aureus infection is critical for
bacterial clearance [138]; however, excessive neutrophil recruitment can result in severe
injury to sensitive lung tissues (reviewed in [42, 139]). Given that MIP-2 levels were
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Figure 3.5 - Lipoproteins limit agr-dependent and agr-independent pulmonary
cytokine expression.
(A) IL-1β (ANOVA p=0.0035), (B) MIP-2 (ANOVA, p<0.0001) and (C) IL-6 levels in
-/-

clarified whole lung homogenate of WT and Pcsk9 mice (A-C, white and gray boxes,
respectively) at 6 hours following intranasal infection with the indicated isolate (N=8
mice per group). Data shown are mean ± SEM. (A-B) ns, not significant; *, p≤0.05, ****,
p≤0.0001, ANOVA with Dunnett’s multiple comparison analysis. (C) *, p≤0.05, Student’s
t-test.
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increased in the lungs of lipoprotein deficient mice infected with LAC, but not with
LAC∆agr, we compared myeloperoxidase (MPO) levels, a surrogate marker of
neutrophil influx, in the lungs of LAC-infected Pcsk9-/- mice versus controls. MPO levels
were significantly higher in the lungs of lipoprotein deficient mice (Figure 3.6A), and
this paralleled an increase in Ly6G+ cells in BALF from 4APP- versus vehicle-treated
mice also infected with LAC (Figure 3.6B). In contrast, neutrophil influx and MPO
levels did not differ between 4APP- and vehicle-treated mice infected with LAC∆agr
(Figure 3.6B) or LAC∆hla (Supplemental Figure 3.2), respectively. Furthermore,
although macrophage levels overall were increased in BALF from LAC-infected versus
LAC∆agr-infected mice (Figure 3.6C), macrophage presence was independent of
circulating lipoprotein levels. Together, these data indicate that lipoproteins are important
for early host control of agr-dependent neutrophil influx during S. aureus lung infection.

ApoB limits agr-dependent cytokine expression by human alveolar
epithelial cells
Murine MIP-2 is a functional homologue of human IL-8, and Hla strongly
induces IL-8 release by human alveolar epithelial cells at toxin concentrations below
those causing cell lysis [140]. To demonstrate that lipoproteins protect against early
inflammatory cytokine production in the lung via inhibition of agr activation, rather than
by direct effects on lung cells or sequestration of agr-regulated virulence factors [65, 126,
141], we measured IL-8 expression by human alveolar epithelial cells exposed to sterile
bacterial supernatant from LAC cultured in the presence versus the absence of LDL.
Consistent with previous reports [80, 123], LDL limited accumulation of Hla in LAC
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Figure 3.6 - Lipoproteins limit agr-dependent neutrophil influx.
(A) MPO levels in whole lung homogenate of WT and Pcsk9

-/-

at 6 hours following

intranasal infection with the indicated isolate (N=8 mice per group). (B) Ly6G+ and (C)
CD11c+ cells in BALF from vehicle- and 4APP-treated mice at 6 hours post-infection.
N=6 (LAC) and 3 (LAC∆agr) mice per group. Data shown are mean ± SEM. ns, not
significant; *, p≤0.05. **, p≤0.01, Student’s t-test.
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culture supernatant (Figure 3.7A), and thus hemolytic activity (Figure 3.7B), whereas
LDL incubated with sterile supernatant post-culture, and either used immediately or after
a one hour co-incubation, did not inhibit hemolysis. Using A549 cells as a model for
human alveolar epithelial cells, LAC supernatant induced il-8 transcription in a dosedependent manner (Figure 3.7C). Furthermore, compared to IL-8 release following
exposure to LAC supernatant, IL-8 production by A549 cells was significantly reduced
when exposed to supernatant from LAC cultured in the presence of LDL (Figure 3.7D).
This reduction in IL-8 was not due to direct effects of LDL on the A549 cells as LDL
incubated with cells for one hour prior to the addition of LAC supernatant did not inhibit
IL-8 production. Also, while there was a small reduction in IL-8 levels when LDL was
co-incubated with LAC supernatant for one hour prior to addition to the A549 cells, this
reduction did not reach statistical significance. This suggests that the impact of LDL on
IL-8 expression in these assays is mainly independent of sequestration of virulence
factors or pathogen associated molecular patterns (PAMPs) within the supernatant [65,
126, 141]. Importantly, IL-8 production did not significantly differ between cells exposed
to supernatant from LAC cultured with LDL and supernatant from cultures of LAC∆agr
or LAC∆hla. Therefore, these results support a mechanism whereby apoB limits S.
aureus QS in the lung and protects the host against excessive inflammatory cytokine
production in response to agr-regulated virulence factors.
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Figure 3.7 - Serum lipoproteins limit agr-dependent cytokine expression by human
alveolar epithelial cells.
(A) Western blot analysis and (B) functional assay of Hla in 6 hour sterile supernatant
from LAC cultured ± LDL (100 nM), LAC supernatant with LDL (100nM) added postculture, post-culture supernatant incubated with LDL (100nM) for 1h, or supernatant
from LAC∆agr or LAC∆hla. Data shown are mean ± SEM. ANOVA (p<0.0001) with
Dunnett’s multiple comparison post-hoc analysis. ****, p≤0.0001. (C) Transcription of
il-8 relative to hprt by A549 cells following 4 hours incubation with LAC sterile
supernatant at the indicated dilutions, and (D) IL-8 release after 4 hours exposure to 1:10
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dilutions of the following: i) broth control, ii) supernatant from LAC cultured in the
absence of LDL, iii) LAC cultured in the presence of LDL (100nM), iv) LAC supernatant
with LDL added post-culture, v) post-culture supernatant incubated with LDL for 1h or
vi) LDL incubated with cells for 1h followed by addition of post-culture supernatant.
Data shown are mean percent (± SEM) of IL-8 production relative to the no LDL (ii)
control. ANOVA (p<0.0001) with Bonferroni’s multiple comparison post-hoc analysis.
ns, not significant; *, p≤0.05; ****, p≤0.0001.
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Discussion

Considerable attention has been given to the role of hyperlipidemia in
cardiovascular disease, such that the terms dyslipidemia and hyperlipidemia are often
used synonymously [66]. This illustrates the limited consideration given to the potential
health consequences of the other dyslipidemia, severe hypolipidemia and lipoprotein
deficiency, often experienced post-trauma and by other critically ill patients [112-114].
Since hypolipidemia has been clinically associated with bacterial pneumonia [88-90], we
sought to determine the impact of extremely low circulating lipoprotein levels on host
innate defense in the lung. Using a sub-lethal mouse model of S. aureus pneumonia, we
demonstrate that lipoprotein deficiency impairs early pulmonary innate defense against
bacterial pathogenesis. Specifically, apoB is present in the lung early post-infection and
its levels decrease significantly with lipoprotein deficiency. This decrease coincides with
impaired host control of S. aureus agr-signaling, as well as increased agr-dependent
morbidity and inflammation, in alignment with the role of apoB in controlling S. aureus
QS-dependent virulence in the skin [80, 83, 123]. In addition, lipoprotein deficiency
results in an agr-independent increase in pulmonary IL-6 expression, consistent with the
ability of apoB to bind LTA and limit LTA-mediated inflammation [126]. Given that
hyperlipidemia also impairs lung innate defense mechanisms [84], these results strongly
suggest that maintenance of normal serum cholesterol and lipoprotein levels is necessary
for optimal host innate defense in the lung.
The contribution of host lipoproteins to pulmonary innate immunity is not
surprising considering their previously described host defense contributions, together
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with their demonstrated uptake by lung capillary endothelium [92] and carriage on
infiltrating leukocytes [93]. For example, circulating lipoproteins, including LDL and
high density lipoprotein (HDL), non-specifically bind and sequester LPS, thus limiting
endotoxin induced toxicity and lethality [124, 125, 142]. In addition, apoB from LDL and
apolipoproteins A1 and A2 from HDL bind soluble LTA and inhibit LTA-mediated
cytokine release from both human and murine cells [126]. The most pronounced
inhibition comes from LDL which dose-dependently inhibits LTA-mediated IL-6
expression by human PBMCs. In support of this finding, here we show that lipoprotein
deficiency results in significantly increased IL-6 levels in the lungs of S. aureus infected
mice independent of agr status. Although in vivo validation of the role of lipoproteins in
controlling LTA-mediated inflammation in the lung will require comparison of
lipoprotein-sufficient versus -deficient mice following pulmonary administration of LTA
or infection with LTA-deficient S. aureus mutants [143, 144], our data and that of others
suggests that hypolipidemia may broadly impact post-trauma pneumonia susceptibility to
both Gram positive and Gram negative pathogens.
Along with sequestration of AIP, lipoproteins have other roles in host defense
against S. aureus pathogenesis. Specifically, LDL has been reported to bind and partially
inactivate Hla [141], while the phenol soluble modulins (PSMs) [122, 145, 146], which
attract and lyse neutrophils, are also bound by lipoproteins, in particular by HDL [65]. In
this regard, the data reported here indicate that LDL limits IL-8 production by human
alveolar epithelial cells by inhibiting expression and secretion of agr-regulated virulence
factors. This is supported by our findings that (i) A549 cells produce IL-8 when exposed
to LAC sterile supernatant, but not when exposed to sterile supernatant from LAC∆agr or
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LAC∆hla, (ii) that inclusion of LDL during LAC culture limits both Hla accumulation in
the supernatant [80, 123] and the ability of the resulting supernatant to induce IL-8
release by A549 cells and (iii) that the addition of LDL to directly to LAC supernatant
does not inhibit IL-8 release by A549 cells. Although these data suggest that LDL
primarily functions by prevention of virulence factor expression in this system,
lipoproteins may also directly inhibit virulence factor function in the lung. Here,
pulmonary administration of LAC supernatant, purified Hla or PSMs to serum
lipoprotein-sufficient versus -deficient mice would further clarify this issue. Regardless,
our findings and those of others [65, 66, 84, 124-126, 141] strongly suggest that
lipoproteins likely contribute in a variety of both direct and indirect means to pulmonary
host innate defense.
In addition to the negative effects of lipoprotein deficiency on pulmonary innate
immunity reported here, severe hypolipidemia may also impair the innate defense
function of lung surfactant (reviewed in [86]). Lung surfactant is comprised of a mixture
of lipids, phospholipids and proteins, and maintenance of the appropriate ratios of these
components is required for functional surfactant self-assembly [85, 147, 148]. Of
particular importance to surfactant-mediated host innate defense are the surfactantassociated proteins, SP-A and SP-D, which act as opsonins to promote bacterial clearance
[149-153]. Since lipoproteins contribute to the regulation of surfactant cholesterol
metabolism [154], it is unclear whether severe hypolipidemia results in impaired
surfactant assembly and negatively impacts bacterial clearance by altering the distribution
or otherwise impairing the antibacterial functions of SP-A and SP-D. While we saw no
evidence of impaired pulmonary bacterial clearance in lipoprotein deficient mice at the
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early post-infection time point investigated here, the potential impact of severe
hypolipidemia on pulmonary bacterial clearance warrants further investigation.
By focusing on early control of S. aureus QS in the lung, we have demonstrated
one mechanism by which severe hypolipidemia impairs pulmonary host innate defense.
Although a significant gap in knowledge remains regarding the full impact of
hypolipidemia on infection susceptibility, disease progression and survival during
pneumonia caused by S. aureus and other microbial pathogens, the work reported here
regarding hypolipidemia, together with the work of others focused on hyperlipidemia
[84], represent important advances in understanding the impact of both extremes of
dyslipidemia on pulmonary host innate defense. Furthermore, these studies point to the
potential clinical impact of severe hypolipidemia on pulmonary innate defense in
critically ill patients.
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Supplemental Information

Supplimental Figure 3.8 - agr-regulated transcription is increased in LAC collected
by BAL from lipoprotein deficient mice.
Bacteria in BALF was collected at six hours following intranasal infection of vehicle- or
4APP-treated mice. Relative quantification (RQ) of RNAIII and lukS-PV transcription
relative to 16S was determined by qRT-PCR. Data shown as mean ± SEM. N= 8 mice per
group. *, p≤0.05; **, p≤0.01, Student’s t-test.
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Supplimental Figure 3.9 - Percent weight loss is increased in LAC infected
lipoprotein deficient mice.
Vehicle- or 4APP-treated (left) and B6 x 129 (WT) or Pcsk9-/- mice (right) were
intranasally infected with agr::P3-YFP LAC (4 x 108 CFU). Mice were weighed at the
time of infection and at 6 hours post-infection. Data shown as median and 5th-95th
percentile. N= 7-8 mice per group. *, p≤0.05; **, p≤0.01, Mann-Whitney test.
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Supplimental Figure 3.10 - MPO levels in lung homogenate from LAC∆hla infected
mice.
MPO in whole lung homogenate of vehicle- and 4APP-treated mice at 6 hours following
intranasal infection with LAC∆hla. Data shown as mean ± SEM. N= 12 mice per group.
ns, not significant, Student’s t-test.
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Chapter 4 – Discussion

There is a growing body of evidence in the literature for lipoprotein particles as
contributors to host innate immunity against a multitude of pathogens [55-66] (Table 1).
However, aside from data presented in Chapter 3, there is no direct evidence showing
how hypolipidemia affects pulmonary innate immunity. Investigation of the contributions
of lipoproteins to pulmonary innate immunity presents a unique opportunity to
understand the potentially complicated interplay of lipoproteins, the immune system, and
related host-pathogen interactions.
Given that most research on the consequences of dyslipidemia has been largely
focused on hyperlipidemia, due to its impact on cardiovascular disease [46-49], there is a
critical gap in knowledge as to what role hypolipidemia may play in pulmonary host
innate immune defense. The potential negative effects and associations of hypolipidemia
include impacts on plasma membrane composition and fluidity, increased risk of cerebral
hemorrhage, adrenal failure, and mortality during sepsis and other critically ill states,
such as extreme trauma or pneumonia [155-161]. In Chapter 3, we presented evidence
that very low apoB containing serum lipoprotein levels during S. aureus pneumonia leads
to increased QS, resulting in increased inflammation and neutrophil recruitment to the
lung at early time points of infection (Figure 4.1). To our knowledge, this is the first
indication that reduced serum lipoproteins impair innate immune defense during
pulmonary infection.
Despite the growing body of evidence that lipoproteins play an important role in
innate immunity, there are still many gaps in knowledge to address, including i) what are
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Figure 4.1 – ApoB in pulmonary defense against S. aureus.
Lowered apoB-containing serum lipoprotein levels during S. aureus pneumonia leads to
increased QS, resulting in increased inflammation and neutrophil recruitment to the lung
at early time points of infection.

62

effects of hypolipidemia on lung surfactant structure and function in innate immunity? ii)
what are the effects of hypolipidemia directly on pulmonary immune cells and
inflammation? and iii) how do cholesterol lowering dependent and independent effects of
drugs, such as statins, contribute to pulmonary infection outcomes? Herein we address
these gaps in knowledge based on the available literature, as well as discuss how
hypolipidemia may affect infection with other lung pathogens, some of the pros and cons
of hyper- and hypolipidemia in infection and immunity, and highlight the concept that
either extreme of dyslipidemia can have negative consequences in pulmonary infection
and immunity.

i) Serum lipoprotein and pulmonary surfactant structure and function

Pulmonary surfactants are primarily composed of lipids and cholesterol and
function to lower surface tension at the air-to-surface interface in the lung, as well as help
serve as a physical barrier for removal of particulates from the lung [162]. Abnormal
levels of cholesterol carrying serum lipoproteins, high or low, have been shown to have
detrimental impacts on pulmonary surfactant structure and ability to function as a surface
tension regulator in the lung [85, 147], consistent with evidence that dyslipidemia in
either direction has negative health effects. The effects of lipoproteins on surfactant
composition, structure and function, as well anti-microbial surfactant proteins, merits
further investigation.
The antimicrobial surfactant proteins SP-A and SP-D interact with a wide variety
of pathogens, including S. aureus, S. pneumoniae, and group A Streptococcus [163-167],
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bind LPS [168], and opsonize bacteria for phagocytosis by alveolar macrophages (AM)
[152]. Interestingly, serum proteins can inhibit surfactant surface tension lowering
activity [169, 170], and SP-A reduces this inhibition [171], suggesting a potential role
for serum proteins in regulating normal lung function during infection. Hypolipidemic
states may contribute to dysregulation of the interplay of lung specific factors, such as
SP-A and SP-D, leading to worse clinical outcomes in patient populations that are more
susceptible to pulmonary infection with a multitude of pathogens.
Despite this, the effects of hypolipidemia on SP-A and SP-D function and
potential consequences for how it might affect gene regulation or protein expression
during pulmonary infection, has not been investigated. Given that we know lipoproteins
can have detrimental effects on lung surfactants, and that serum lipoprotein levels effect
lipoprotein levels in the lung, we hypothesize that SP-A and SP-D function and
regulation may be affected by serum lipoprotein levels, leading to different outcomes
during pulmonary infection in an in vivo model. Include collected lung samples for qRTPCR of SP-A/SP-D To test this, we would first consider the effects of the addition of
serum lipoproteins on SP-A and SP-D expression and secretion from A549 cells
[172].Additionally, regulation of SP-A and SP-D in our hypolipidemic mouse models
(detailed in Chapter 3), compared to controls would represent an important next
evaluation. The results of these experiments could have further implications in the
contributions of serum lipoproteins in pulmonary innate immunity against a variety of
pathogens.
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ii) Serum lipoproteins modulate the inflammatory response

In addition to the potential effects of lipoproteins on physical immune barriers
such as surfactant and associated surfactant proteins, we know from studies of
atherosclerosis that serum lipoproteins can also modulate inflammatory responses in
many different cell types [173]. For example, exposure of macrophages to modified LDL
increases expression of the oxidized LDL (oxLDL) scavenger receptor, CD36, which
contributes to development of foam cells in auto-immune development of atherosclerotic
lesions [174]. OxLDL can also induce monocyte chemoattractant protein-1 (MCP-1)
expression from endothelial cells, inhibit macrophage migration, and induce
proinflammatory cytokine expression from macrophages [173]. SP-A has also been
shown to induce respiratory burst and nitric oxide synthase (NOS) expression in AMs
[32]. Furthermore, uptake of LDL by the LDLR on neutrophils transiently increases their
oxidative burst [175], which is important in auto-immune development of atherosclerosis
via oxidative modification of LDL, as well as important in microbial killing.
Unsurprisingly, systemic oxidation of lipoproteins occurs during the acute phase response
to LPS induced septic shock [176]. Myeloperoxidase (MPO) produced by neutrophils
during infection is important in oxidative killing of microbes via production of cell
generated hypochlorous acid, which can also oxidize lipoproteins [177]. Additionally,
HDL has also been shown to mediate anti-inflammatory reprogramming of macrophages
through reduced expression of TLR-induced cytokines [178], to attenuate neutrophil
activation via reduction of lipid raft abundance associated with CD11b activation [179],
and limit the oxidative burst of neutrophils by oxLDL [180]. Based on these studies, it is
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clear that lipoproteins play an important role in helping activate inflammatory responses,
are modified by ROS produced by activated leukocytes, and that these modified
lipoproteins can further modulate inflammation. However, since most atherosclerosis
research is done in hyperlipidemic models, there is a need to address how extreme
hypolipidemia may affect innate immune cell signaling and function, particularly in the
context of pulmonary infection.
Despite the wealth of research on lipoproteins in atherosclerosis, there is
conflicting literature regarding the effects lipoproteins and cholesterol can have both
detrimental and beneficial immunomodulatory and inflammatory effects during
infections. For example, exposure of guinea pigs to Mycobacterium tuberculosis
increases expression of CD36 on AMs, thus increasing uptake of oxLDL by AMs
resulting in increased intracellular bacterial survival [181], likely due to use of
cholesterol as a carbon source by M. tuberculosis. Additionally, deletion of the ATPbinding cassette transporter A1 (ABCA1), which plays a role in efflux of intracellular
free cholesterol, has been shown to increase resistance to infection via increases in the
proinflammatory state of macrophages, in a mouse model of intraperitoneal Listeria
monocytogenes [182]. The deletion of ABCA1 also resulted in higher systemic
concentrations of MCP-1, MIP-2, and IL-6. Given our findings showing association of
elevated MIP-2 and neutrophil recruitment with worse disease outcomes in the lung in
lipoprotein deficient mice, one may expect that a mutation which causes dysfunction in
ABCA1, and the associated lipid metabolism differences could have different effects in a
pulmonary disease model. Interestingly, cholesterol crystals have been shown to prime
neutrophils to release neutrophil extracellular traps (NETs), prime macrophages to
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release IL-1β, and activate T helper 17 cells which increase immune cell recruitment
[183]. It has also been hypothesized that oxidation-specific epitopes on oxLDL that are
similar to epitopes on pathogens, serve to maintain natural antibodies against those
pathogens [184]. Together, these varied studies indicate the complex interplay of
lipoproteins and the immune system and the importance of both extremes of dyslipidemia
to negative disease states or infection outcomes. Given this, and the increased presence of
serum lipoproteins in the lung during infection, a role for lipoproteins in directly
modulating inflammation during pulmonary infection may be indicated.

iii) Statins in innate immunity and pleotropic effects on inflammation

Statins as treatments for lowering cholesterol can dramatically reduce instances of
cardiovascular disease [185, 186]. In contrast to the idea that severe reduction in
cholesterol levels could knockdown serum lipoproteins as an innate immune barrier [87],
statins appear to have some beneficial effects in severe infectious disease outcomes. For
example, in a clinical study of 575 patients, looking at pre-hospitalization use of statins,
beneficial effects were found in lowering rates of sepsis and pneumonia in humans during
early critical illness [187]. A conflicting clinical study’s results showed no benefits to 90day mortality rates in community acquired pneumonia (CAP) patients, and no significant
elevation in plasma markers of severe sepsis and CAP, such as inflammatory cytokines
and leukocyte cell surface protein expression markers [188]. However, the authors of this
study still suggest that the trends favored statin usage over no statin usage, and suggest
(while not statistically significant) a potentially clinically meaningful benefit of statin

67

usage in CAP cases. While prophylactic usage of statins appeared to have beneficial
effects in these severe disease outcomes, post-hospitalization treatment with statins
appeared to have no effect in either study [187, 188].
The suggestion that statins have a clinically beneficial role in severe disease
outcomes merits further investigation into the mechanisms behind this benefit.
Laboratory investigations found that simvastatin may play a role in inhibiting the actin
dynamics in human endothelial cells required for S. aureus endocytosis and invasion
[189], inhibit LTA induced inflammation in human AMs through inhibition of NF-κB
activation [190], and enhance extracellular trap formation by human and murine
leukocytes via inhibition of sterol production [191]. Another study found that simvastatin
and pravastatin (at sub-cholesterol lowering concentrations) were able to limit the
cytotoxicity of Hla and pneumolysin, a major pore forming toxin of S. pneumoniae ,
against human airway epithelial cells [192], and that the mechanism for this was
independent of the cholesterol-lowering mevalonate pathways. These studies indicate that
statins have a pleotropic role in lowering damaging inflammatory responses via
mechanisms independent of their targeted use against cardiovascular disease. This further
indicates the complicated and sometimes paradoxical interplay of the pulmonary immune
milieu in clearing infection, through phagocytosis and killing of bacterial pathogens,
while simultaneously limiting potentially damaging inflammation. These findings present
interesting avenues for research looking at these effected pathways for lowering initial
inflammatory responses in severe infection cases.
Despite evidence suggesting that statin usage may be beneficial in severe sepsis
and pulmonary disease outcomes, there are no reports looking at statin usage and the state
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of hypolipidemia during severe pulmonary infection. The evidence showing subcholesterol lowering, anti-inflammatory effects of statins may indicate confounding
variables in statin using patients in extreme hypolipidemic states and merits further
investigation. We propose that sub-cholesterol lowering concentrations of statins could
have beneficial immunomodulatory effects on inflammatory signaling, and detrimental
effects during infection at higher concentrations (relevant to CVD treatment) via further
knockdown of lipoproteins as innate immune barriers. Given the wide usage of statins,
perhaps this could be elucidated by doing a database search of clinical outcomes in
hypolipidemic patient populations (such as in the case of severe trauma), comparing
statin and non-statin users. We would also suggest experiments to test the effects of
simvastatin treatment at previously reported sub-cholesterol reduction levels (10 nM to
1000 nM) [192] in a lipoprotein deficient mouse model of S. aureus pulmonary infection,
compared to control mice. We would predict that pre-infection statin treatment would
have beneficial effects in control mice at sub-cholesterol reducing levels, but increase QS
and resulting inflammation and disease in lipoprotein deficient mice. The results of these
studies could point to sub-cholesterol reducing levels of statins as potential treatments in
critically ill patient populations.
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Closing comments

Lipoprotein research has been primarily focused in the area of hyperlipidemia,
largely because of its known association with increased CVD and atherosclerosis.
Through this, the scientific community’s understanding of lipoproteins as immune system
modulators and causes of immune dysfunction in these disease states, is vast. Perhaps
naturally arising from this large body of research is more recent research showing that
hyperlipidemia

has

important

consequences

in

infectious

disease

outcomes

(Madenspacher et al., 2010, From Paper), and that infectious agents can also enhance
disease progression in CVD and atherosclerosis (Dutta et al. 2009, Repeated Systemic).
However, there is comparatively very little research on the effects of hypolipidemic states
and their contributions to infectious disease.
Given the importance of CVD and atherosclerosis, statins have become some of
the most prescribed drugs world-wide (Herbert et al. 1997, Cholesterol Lowering, Gotto
1997, Cholesterol Management). However, because of the limited research done on the
effects of hypolipidemia during trauma and outcomes in infectious disease, the
consequences of statins as reducers of lipoproteins as an innate immune barrier in these
populations has not been accurately assessed. Furthermore, whether the potentially
beneficial effects of statins that are unrelated to their ability to lower cholesterol are
outweighed by further knockdown of lipoproteins as agents of innate immunity has not
been thoroughly investigated in hypolipidemic patient populations.
One of the hallmarks of susceptibility to infection is a compromised immune
system. Perhaps not coincidentally, individuals recovering from traumatic insult are
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likely to have lowered serum levels of circulating apoB containing lipoproteins, and are
more susceptible to infection [91]. Addressing the gaps in knowledge described above
may have implications in early prediction of pneumonia susceptibility in trauma patients.
Perhaps lipoproteins as potential future treatment options could ultimately help contribute
to better outcomes in hypolipidemic patients who are more susceptible to infection.
Additionally, the studies discussed herein suggest that lipoproteins could serve as an
innate immune barrier during early infection in the lung against a multitude of pathogens.
The lung is particularly sensitive to damage caused by infectious disease and
inflammation. Due to the lungs indispensability as an organ, pneumonia in particular is
an important and severe disease state, resulting in overall high levels of morbidity and
mortality. Though the lung has become highly adapted with physical barriers, and unique
antimicrobial agents and resident immune cells, likely because of these very reasons, it
also presents a unique disease microenvironment where lipoproteins may have even
further pleotropic effects beyond direct innate immune agents and inflammatory signaling
modulators. Based on the presented research, as well as our own findings, dyslipidemia in
either direction appears to have detrimental effects in infectious disease outcomes in
pulmonary infection. Both over activation of inflammatory signaling and lack of infection
control may be particularly detrimental in the lung, with over activation of inflammatory
signaling leading to increased inflammation induced damage. Perhaps when dyslipidemia
in either direction can cause dysregulation of inflammatory signaling, or deficiencies in
innate immunity and ultimately lack of pathogen control, leading to increased toxin
induced inflammation and tissue damage.
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Appendix A: Abbreviations

4APP

4-aminopyrizolo[3,4-d]pyrimidine

agr

Accessory gene regulator

AIP

Auto-inducing peptide

AM

Alveolar macrophage

AMP

Antimicrobial peptide

ApoA1

Apolipoprotein A1

ApoA2

Apolipoprotein A2

ApoB

Apolipoprotein B

ApoB-48

N-terminal 48% of apolipoprotein B

ApoC1

Apolipoprotein C1

ApoC2

Apolipoprotein C2

ApoE

Apolipoprotein E

APR

Acute phase response

BALF

Bronchial alveolar lavage fluid

BCIP

5-bromo-4-chloro-3-indolyl-phosphate

BSA

Bovine serum albumin

CA-MRSA

Community acquired methicillin-resistant Staphylococcus aureus

CAP

Community acquired pneumonia

CDC

Centers for Disease Control

cDNA

Complimentary deoxyribonucleic acid

CFU

Colony forming unit
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CVD

Cardiovascular disease

DC

Dendritic cell

HAP

Hospital acquired pneumonia

HDL

High density lipoprotein

Hla

Alpha-hemolysin

hLDL

Human low density lipoprotein

i.n.

Intranasal

LDL

Low density lipoprotein

LDLR

Low density lipoprotein receptor

LPS

Lipopolysaccharide

LTA

Lipoteichoic acid

mAb

Mouse antibody

MCF

Mean channel fluorescence

MPO

myeloperoxidase

MRSA

Methicillin-resistant Staphylococcus aureus

NBT

Nitroblue tetrazolium

NET

Neutrophil extracellular trap

NK

Natural killer cell

NOS

Nitric oxide synthase

ns

Not significant

oxLDL

Oxidized low density lipoprotein

PAGE

Polyacrylamide gel electrophoresis

PAMP

Pathogen-associated molecular pattern
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PBMC

Peripheral blood mononuclear cell

PBS

Phosphate buffered saline

PSM

Phenol soluble modulins

PVDF

Polyvinylidene fluoride

PVL

Panton-Valentine leucocidin

qRT-PCR

Quantitative real-time polymerase chain reaction

QS

Quorum sensing

RBC

Red blood cell

RNA

Ribonucleic acid

RNS

Reactive nitrogen species

ROS

Reactive oxygen species

RQ

Relative quantification

RT

Reverse transcriptase

SEM

Standard error of the mean

SSSI

Skin and skin structure infection

TBS

Tris buffered saline

TLR

Toll-like receptor

TSB

Tryptic Soy Broth

VLDL

Very low density lipoprotein

WT

Wild-type

YFP

Yellow fluorescent protein

74

References
1.

Williams, R.E., Healthy carriage of Staphylococcus aureus: its prevalence and
importance. Bacteriol Rev, 1963. 27: p. 56-71.

2.

Ballinger, M.N. and T.J. Standiford, Postinfluenza bacterial pneumonia: host
defenses gone awry. J Interferon Cytokine Res, 2010. 30(9): p. 643-52.

3.

Kollef, M.H., et al., Epidemiology and outcomes of health-care-associated
pneumonia: results from a large US database of culture-positive pneumonia.
Chest, 2005. 128(6): p. 3854-62.

4.

Rubinstein, E., M.H. Kollef, and D. Nathwani, Pneumonia caused by methicillinresistant Staphylococcus aureus. Clin Infect Dis, 2008. 46 Suppl 5: p. S378-85.

5.

Engemann, J.J., et al., Adverse clinical and economic outcomes attributable to
methicillin resistance among patients with Staphylococcus aureus surgical site
infection. Clin Infect Dis, 2003. 36(5): p. 592-8.

6.

Gordon, R.J. and F.D. Lowy, Pathogenesis of methicillin-resistant
Staphylococcus aureus infection. Clin Infect Dis, 2008. 46 Suppl 5: p. S350-9.

7.

CDC, Antibiotic Resistance Threats in the United States, 2013, 2013.

8.

Novick, R.P. and E. Geisinger, Quorum sensing in staphylococci. Annu Rev
Genet, 2008. 42: p. 541-64.

9.

Wuster, A. and M.M. Babu, Conservation and evolutionary dynamics of the agr
cell-to-cell communication system across firmicutes. J Bacteriol, 2008. 190(2): p.
743-6.

10.

Reynolds, J. and S. Wigneshweraraj, Molecular insights into the control of
transcription initiation at the Staphylococcus aureus agr operon. J Mol Biol,
2011. 412(5): p. 862-81.
Morfeldt, E., et al., Activation of alpha-toxin translation in Staphylococcus aureus
by the trans-encoded antisense RNA, RNAIII. EMBO J, 1995. 14(18): p. 4569-77.

11.

12.

Bubeck Wardenburg, J., et al., Poring over pores: alpha-hemolysin and PantonValentine leukocidin in Staphylococcus aureus pneumonia. Nat Med, 2007.
13(12): p. 1405-6.

13.

Bubeck Wardenburg, J., R.J. Patel, and O. Schneewind, Surface proteins and
exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia.
Infect Immun, 2007. 75(2): p. 1040-4.
75

14.

Inoshima, N., Y. Wang, and J. Bubeck Wardenburg, Genetic requirement for
ADAM10 in severe Staphylococcus aureus skin infection. J Invest Dermatol,
2012. 132(5): p. 1513-6.

15.

Powers, M.E., et al., ADAM10 mediates vascular injury induced by
Staphylococcus aureus alpha-hemolysin. J Infect Dis, 2012. 206(3): p. 352-6.

16.

Bhakdi, S. and J. Tranum-Jensen, Alpha-toxin of Staphylococcus aureus.
Microbiol Rev, 1991. 55(4): p. 733-51.

17.

Inoshima, I., et al., A Staphylococcus aureus pore-forming toxin subverts the
activity of ADAM10 to cause lethal infection in mice. Nat Med, 2011. 17(10): p.
1310-4.

18.

Kebaier, C., et al., Staphylococcus aureus alpha-hemolysin mediates virulence in
a murine model of severe pneumonia through activation of the NLRP3
inflammasome. J Infect Dis, 2012. 205(5): p. 807-17.

19.

Kaneko, J. and Y. Kamio, Bacterial two-component and hetero-heptameric poreforming cytolytic toxins: structures, pore-forming mechanism, and organization of
the genes. Biosci Biotechnol Biochem, 2004. 68(5): p. 981-1003.

20.

Shallcross, L.J., et al., The role of the Panton-Valentine leucocidin toxin in
staphylococcal disease: a systematic review and meta-analysis. Lancet Infect Dis,
2013. 13(1): p. 43-54.

21.

Labandeira-Rey, M., et al., Staphylococcus aureus Panton-Valentine leukocidin
causes necrotizing pneumonia. Science, 2007. 315(5815): p. 1130-3.

22.

Bubeck Wardenburg, J., et al., Panton-Valentine leukocidin is not a virulence
determinant in murine models of community-associated methicillin-resistant
Staphylococcus aureus disease. J Infect Dis, 2008. 198(8): p. 1166-70.

23.

Montgomery, C.P. and R.S. Daum, Transcription of inflammatory genes in the
lung after infection with community-associated methicillin-resistant
Staphylococcus aureus: a role for panton-valentine leukocidin? Infect Immun,
2009. 77(5): p. 2159-67.

24.

Villaruz, A.E., et al., A point mutation in the agr locus rather than expression of
the Panton-Valentine leukocidin caused previously reported phenotypes in
Staphylococcus aureus pneumonia and gene regulation. J Infect Dis, 2009.
200(5): p. 724-34.

25.

Wang, R., et al., Identification of novel cytolytic peptides as key virulence
determinants for community-associated MRSA. Nat Med, 2007. 13(12): p. 1510-4.

76

26.

Berube, B.J., et al., The psmalpha locus regulates production of Staphylococcus
aureus alpha-toxin during infection. Infect Immun, 2014. 82(8): p. 3350-8.

27.

Cheung, G.Y., et al., Insight into structure-function relationship in phenol-soluble
modulins using an alanine screen of the phenol-soluble modulin (PSM) alpha3
peptide. FASEB J, 2014. 28(1): p. 153-61.

28.

Kaito, C., et al., Transcription and translation products of the cytolysin gene psmmec on the mobile genetic element SCCmec regulate Staphylococcus aureus
virulence. PLoS Pathog, 2011. 7(2): p. e1001267.

29.

Whitsett, J.A. and T. Alenghat, Respiratory epithelial cells orchestrate pulmonary
innate immunity. Nat Immunol, 2015. 16(1): p. 27-35.

30.

Tecle, T., S. Tripathi, and K.L. Hartshorn, Review: Defensins and cathelicidins in
lung immunity. Innate Immun, 2010. 16(3): p. 151-9.

31.

Janssen, W.J., et al., Surfactant proteins A and D suppress alveolar macrophage
phagocytosis via interaction with SIRP alpha. Am J Respir Crit Care Med, 2008.
178(2): p. 158-67.

32.

Hickman-Davis, J.M., et al., Lung surfactant and reactive oxygen-nitrogen
species: antimicrobial activity and host-pathogen interactions. Am J Physiol
Lung Cell Mol Physiol, 2001. 281(3): p. L517-23.

33.

DiMango, E., et al., Diverse Pseudomonas aeruginosa gene products stimulate
respiratory epithelial cells to produce interleukin-8. J Clin Invest, 1995. 96(5): p.
2204-10.

34.

Marfaing-Koka, A., et al., Regulation of the production of the RANTES chemokine
by endothelial cells. Synergistic induction by IFN-gamma plus TNF-alpha and
inhibition by IL-4 and IL-13. J Immunol, 1995. 154(4): p. 1870-8.

35.

Stellato, C., et al., Expression of the chemokine RANTES by a human bronchial
epithelial cell line. Modulation by cytokines and glucocorticoids. J Immunol,
1995. 155(1): p. 410-8.

36.

Westphalen, K., et al., Sessile alveolar macrophages communicate with alveolar
epithelium to modulate immunity. Nature, 2014. 506(7489): p. 503-6.

37.

Broug-Holub, E. and G. Kraal, Dose- and time-dependent activation of rat
alveolar macrophages by glucocorticoids. Clin Exp Immunol, 1996. 104(2): p.
332-6.

38.

Green, G.M. and E.H. Kass, The Role of the Alveolar Macrophage in the
Clearance of Bacteria from the Lung. J Exp Med, 1964. 119: p. 167-76.
77

39.

Gardai, S.J., et al., By binding SIRPalpha or calreticulin/CD91, lung collectins
act as dual function surveillance molecules to suppress or enhance inflammation.
Cell, 2003. 115(1): p. 13-23.

40.

Adkins, K.K., et al., Glucocorticoid regulation of GM-CSF: evidence for
transcriptional mechanisms in airway epithelial cells. Am J Physiol, 1998. 275(2
Pt 1): p. L372-8.

41.

Eisele, N.A. and D.M. Anderson, Host Defense and the Airway Epithelium:
Frontline Responses That Protect against Bacterial Invasion and Pneumonia. J
Pathog, 2011. 2011: p. 249802.

42.

Craig, A., et al., Neutrophil recruitment to the lungs during bacterial pneumonia.
Infect Immun, 2009. 77(2): p. 568-75.

43.

Rosseau, S., et al., Monocyte migration through the alveolar epithelial barrier:
adhesion molecule mechanisms and impact of chemokines. J Immunol, 2000.
164(1): p. 427-35.

44.

Vance, D.E. and J.E. Vance, Biochemistry of lipids, lipoproteins, and membranes.
New comprehensive biochemistry. 1996, Amsterdam ; New York: Elsevier. xxii,
553 p.

45.

Rye, K.A., et al., The metabolism and anti-atherogenic properties of HDL. J Lipid
Res, 2009. 50 Suppl: p. S195-200.

46.

Wouters, K., et al., Understanding hyperlipidemia and atherosclerosis: lessons
from genetically modified apoe and ldlr mice. Clin Chem Lab Med, 2005. 43(5):
p. 470-9.

47.

Nilsson, J., H. Bjorkbacka, and G.N. Fredrikson, Apolipoprotein B100
autoimmunity and atherosclerosis - disease mechanisms and therapeutic
potential. Curr Opin Lipidol, 2012. 23(5): p. 422-8.

48.

Fredrikson, G.N., et al., Inhibition of atherosclerosis in apoE-null mice by
immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol,
2003. 23(5): p. 879-84.

49.

Pierides, C., et al., Immune responses elicited by apoB-100-derived peptides in
mice. Immunol Res, 2013. 56(1): p. 96-108.

50.

Bjorkhem-Bergman, L., et al., Statin treatment and mortality in bacterial
infections--a systematic review and meta-analysis. PLoS One, 2010. 5(5): p.
e10702.

78

51.

Kopterides, P. and M.E. Falagas, Statins for sepsis: a critical and updated review.
Clin Microbiol Infect, 2009. 15(4): p. 325-34.

52.

Terblanche, M., et al., Statins and sepsis: multiple modifications at multiple
levels. Lancet Infect Dis, 2007. 7(5): p. 358-68.

53.

Miida, T., S. Hirayama, and Y. Nakamura, Cholesterol-independent effects of
statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler
Thromb, 2004. 11(5): p. 253-64.

54.

Wang, J., et al., Effects of different statins on endothelial nitric oxide synthase and
AKT phosphorylation in endothelial cells. Int J Cardiol, 2008. 127(1): p. 33-9.

55.

Kelly, B.A., et al., Anti-infective activity of apolipoprotein domain derived
peptides in vitro: identification of novel antimicrobial peptides related to
apolipoprotein B with anti-HIV activity. BMC Immunol, 2010. 11: p. 13.

56.

Bhakdi, S., et al., Binding and partial inactivation of Staphylococcus aureus
alpha-toxin by human plasma low density lipoprotein. J Biol Chem, 1983. 258(9):
p. 5899-904.

57.

Han, R., Plasma lipoproteins are important components of the immune system.
Microbiol Immunol, 2010. 54(4): p. 246-53.

58.

Omae, Y., et al., Silkworm apolipophorin protein inhibits hemolysin gene
expression of Staphylococcus aureus via binding to cell surface lipoteichoic
acids. J Biol Chem, 2013. 288(35): p. 25542-50.

59.

Hanada, Y., K. Sekimizu, and C. Kaito, Silkworm apolipophorin protein inhibits
Staphylococcus aureus virulence. J Biol Chem, 2011. 286(45): p. 39360-9.

60.

Thaveeratitham, P., et al., Effects of human apolipoprotein A-I on endotoxininduced leukocyte adhesion on endothelial cells in vivo and on the growth of
Escherichia coli in vitro. J Endotoxin Res, 2007. 13(1): p. 58-64.

61.

Biedzka-Sarek, M., et al., Apolipoprotein A-I exerts bactericidal activity against
Yersinia enterocolitica serotype O:3. J Biol Chem, 2011. 286(44): p. 38211-9.

62.

Estin, M.L., D.A. Stoltz, and J. Zabner, Paraoxonase 1, quorum sensing, and P.
aeruginosa infection: a novel model. Adv Exp Med Biol, 2010. 660: p. 183-93.

63.

Furlong, C.E., et al., Human PON1, a biomarker of risk of disease and exposure.
Chem Biol Interact, 2010. 187(1-3): p. 355-61.

79

64.

Stoltz, D.A., et al., Drosophila are protected from Pseudomonas aeruginosa
lethality by transgenic expression of paraoxonase-1. J Clin Invest, 2008. 118(9):
p. 3123-31.

65.

Surewaard, B.G., et al., Inactivation of staphylococcal phenol soluble modulins by
serum lipoprotein particles. PLoS Pathog, 2012. 8(3): p. e1002606.

66.

Gowdy, K.M. and M.B. Fessler, Emerging roles for cholesterol and lipoproteins
in lung disease. Pulm Pharmacol Ther, 2013. 26(4): p. 430-7.

67.

Sigel, S., et al., Apolipoprotein B100 is a suppressor of Staphylococcus aureusinduced innate immune responses in humans and mice. Eur J Immunol, 2012.
42(11): p. 2983-9.

68.

Harris, H.W., et al., Human very low density lipoproteins and chylomicrons can
protect against endotoxin-induced death in mice. J Clin Invest, 1990. 86(3): p.
696-702.

69.

Hao, J. and X.D. He, Haplotype analysis of ApoAI gene and sepsis-associated
acute lung injury. Lipids Health Dis, 2014. 13: p. 79.

70.

Pridgeon, J.W. and P.H. Klesius, Apolipoprotein A1 in channel catfish:
transcriptional analysis, antimicrobial activity, and efficacy as plasmid DNA
immunostimulant against Aeromonas hydrophila infection. Fish Shellfish
Immunol, 2013. 35(4): p. 1129-37.

71.

Pays, E. and B. Vanhollebeke, Human innate immunity against African
trypanosomes. Curr Opin Immunol, 2009. 21(5): p. 493-8.

72.

Westerterp, M., et al., Apolipoprotein C-I is crucially involved in
lipopolysaccharide-induced atherosclerosis development in apolipoprotein Eknockout mice. Circulation, 2007. 116(19): p. 2173-81.

73.

Ng, P.C., et al., Host-response biomarkers for diagnosis of late-onset septicemia
and necrotizing enterocolitis in preterm infants. J Clin Invest, 2010. 120(8): p.
2989-3000.

74.

Toledo, A., et al., Hypercholesterolemia and ApoE deficiency result in severe
infection with Lyme disease and relapsing-fever Borrelia. Proc Natl Acad Sci U S
A, 2015. 112(17): p. 5491-6.

75.

Palusinska-Szysz, M., et al., Analysis of cell surface alterations in Legionella
pneumophila cells treated with human apolipoprotein E. Pathog Dis, 2015. 73(2):
p. 1-8.

80

76.

Poole, S., et al., Active invasion of Porphyromonas gingivalis and infectioninduced complement activation in ApoE-/- mice brains. J Alzheimers Dis, 2015.
43(1): p. 67-80.

77.

Gale, S.C., et al., APOepsilon4 is associated with enhanced in vivo innate immune
responses in human subjects. J Allergy Clin Immunol, 2014. 134(1): p. 127-34.

78.

Azevedo, O.G., et al., Apolipoprotein E plays a key role against cryptosporidial
infection in transgenic undernourished mice. PLoS One, 2014. 9(2): p. e89562.

79.

Dobson, C.B., et al., The receptor-binding region of human apolipoprotein E has
direct anti-infective activity. J Infect Dis, 2006. 193(3): p. 442-50.

80.

Peterson, M.M., et al., Apolipoprotein B Is an innate barrier against invasive
Staphylococcus aureus infection. Cell Host Microbe, 2008. 4(6): p. 555-66.

81.

Hall, P.R., et al., Nox2 modification of LDL is essential for optimal apolipoprotein
B-mediated control of agr type III Staphylococcus aureus quorum-sensing. PLoS
Pathog, 2013. 9(2): p. e1003166.

82.

Bartolome, N., et al., Biphasic adaptative responses in VLDL metabolism and
lipoprotein homeostasis during Gram-negative endotoxemia. Innate Immun,
2012. 18(1): p. 89-99.

83.

Elmore, B.O., K.D. Triplett, and P.R. Hall, Apolipoprotein B48, the Structural
Component of Chylomicrons, Is Sufficient to Antagonize Staphylococcus aureus
Quorum-Sensing. PLoS One, 2015. 10(5): p. e0125027.

84.

Madenspacher, J.H., et al., Dyslipidemia induces opposing effects on
intrapulmonary and extrapulmonary host defense through divergent TLR
response phenotypes. J Immunol, 2010. 185(3): p. 1660-9.

85.

Suzuki, Y. and R. Tabata, Selective reduction of phosphatidylglycerol and
phosphatidylcholine in pulmonary surfactant by 4aminopyrazolo(3,4d)pyrimidine in the rat. J Lipid Res, 1980. 21(8): p. 1090-6.

86.

Chroneos, Z.C., Z. Sever-Chroneos, and V.L. Shepherd, Pulmonary surfactant:
an immunological perspective. Cell Physiol Biochem, 2010. 25(1): p. 13-26.

87.

Elmehdawi, R., Hypolipidemia: a word of caution. Libyan J Med, 2008. 3(2): p.
84-90.

88.

Gruber, M., et al., Prognostic impact of plasma lipids in patients with lower
respiratory tract infections - an observational study. Swiss Med Wkly, 2009.
139(11-12): p. 166-72.

81

89.

Sankaran, R.T., et al., Laboratory abnormalities in patients with bacterial
pneumonia. Chest, 1997. 111(3): p. 595-600.

90.

Chien, Y.F., et al., Decreased serum level of lipoprotein cholesterol is a poor
prognostic factor for patients with severe community-acquired pneumonia that
required intensive care unit admission. J Crit Care, 2015. 30(3): p. 506-10.

91.

Femling, J.K., et al., Nosocomial infections after severe trauma are associated
with lower apolipoproteins B and AII. J Trauma Acute Care Surg, 2013. 74(4): p.
1067-73.

92.

Nistor, A. and M. Simionescu, Uptake of low density lipoproteins by the hamster
lung. Interactions with capillary endothelium. Am Rev Respir Dis, 1986. 134(6):
p. 1266-72.

93.

Alipour, A., et al., Leukocyte activation by triglyceride-rich lipoproteins.
Arterioscler Thromb Vasc Biol, 2008. 28(4): p. 792-7.

94.

Mizgerd, J.P. and S.J. Skerrett, Animal models of human pneumonia. Am J
Physiol Lung Cell Mol Physiol, 2008. 294(3): p. L387-98.

95.

Brain, J.D. and P.A. Valberg, Deposition of aerosol in the respiratory tract. Am
Rev Respir Dis, 1979. 120(6): p. 1325-73.

96.

Toews, G.B., Determinants of bacterial clearance from the lower respiratory
tract. Semin Respir Infect, 1986. 1(2): p. 68-78.

97.

Laurenzi, G.A., et al., A Quantitative Study of the Deposition and Clearance of
Bacteria in the Murine Lung. J Clin Invest, 1964. 43: p. 759-68.

98.

Onofrio, J.M., et al., Granulocyte-alveolar-macrophage interaction in the
pulmonary clearance of Staphylococcus aureus. Am Rev Respir Dis, 1983.
127(3): p. 335-41.

99.

Ginsberg, H.S., et al., A mouse model for investigating the molecular
pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A, 1991. 88(5):
p. 1651-5.

100.

Kimura, K., et al., Factors affecting the course and severity of transnasally
induced Staphylococcus aureus pneumonia in mice. J Med Microbiol, 1999.
48(11): p. 1005-10.

101.

Bubeck Wardenburg, J. and O. Schneewind, Vaccine protection against
Staphylococcus aureus pneumonia. J Exp Med, 2008. 205(2): p. 287-94.

82

102.

Braff, M.H., et al., Staphylococcus aureus exploits cathelicidin antimicrobial
peptides produced during early pneumonia to promote staphylokinase-dependent
fibrinolysis. J Infect Dis, 2007. 195(9): p. 1365-72.

103.

Ragle, B.E. and J. Bubeck Wardenburg, Anti-alpha-hemolysin monoclonal
antibodies mediate protection against Staphylococcus aureus pneumonia. Infect
Immun, 2009. 77(7): p. 2712-8.

104.

Visweswaraiah, A., et al., Tracking the tissue distribution of marker dye following
intranasal delivery in mice and chinchillas: a multifactorial analysis of
parameters affecting nasal retention. Vaccine, 2002. 20(25-26): p. 3209-20.

105.

Southam, D.S., et al., Distribution of intranasal instillations in mice: effects of
volume, time, body position, and anesthesia. Am J Physiol Lung Cell Mol
Physiol, 2002. 282(4): p. L833-9.

106.

Miller, M.A., et al., Visualization of murine intranasal dosing efficiency using
luminescent Francisella tularensis: effect of instillation volume and form of
anesthesia. PLoS One, 2012. 7(2): p. e31359.

107.

Kim, H.K., D. Missiakas, and O. Schneewind, Mouse models for infectious
diseases caused by Staphylococcus aureus. J Immunol Methods, 2014. 410: p. 8899.

108.

Ventura, C.L., et al., Staphylococcus aureus elicits marked alterations in the
airway proteome during early pneumonia. Infect Immun, 2008. 76(12): p. 586272.

109.

Daniels, T.F., et al., Lipoproteins, cholesterol homeostasis and cardiac health.
International journal of biological sciences, 2009. 5(5): p. 474-488.

110.

Collaboration, T.E.R.F., Major Lipids, Apolipoproteins and Risk of Vascular
Disease. JAMA, 2009. 302: p. 1993-2000.

111.

Feingold, K.R. and C. Grunfeld, Lipids: a key player in the battle between the
host and microorganisms. J Lipid Res, 2012. 53(12): p. 2487-9.

112.

Khovidhunkit, W., et al., Effects of infection and inflammation on lipid and
lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res,
2004. 45(7): p. 1169-96.

113.

Vyroubal, P., et al., Hypocholesterolemia in clinically serious conditions–review.
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc,
Czechoslovakia, 2008. 152(2): p. 181-189.

83

114.

Femling, J.K., et al., Nosocomial infections after severe trauma are associated
with lower apolipoproteins B and AII. J Trauma Acute Care Surg, 2013. 74(4): p.
1067-1073.

115.

Rubinstein, E., M.H. Kollef, and D. Nathwani, Pneumonia caused by methicillinresistant Staphylococcus aureus. Clin Infect Dis, 2008. 46 Suppl 5: p. S378-85.

116.

Nakou, A., M. Woodhead, and A. Torres, MRSA as a cause of communityacquired pneumonia. Eur Respir J, 2009. 34(5): p. 1013-1014.

117.

Defres, S., C. Marwick, and D. Nathwani, MRSA as a cause of lung infection
including airway infection, community-acquired pneumonia and hospitalacquired pneumonia. Eur Respir J, 2009. 34(6): p. 1470-1476.

118.

Montgomery, C.P., S. Boyle-Vavra, and R.S. Daum, Importance of the global
regulators Agr and SaeRS in the pathogenesis of CA-MRSA USA300 infection.
PLoS One, 2010. 5(12): p. e15177.

119.

Heyer, G., et al., Staphylococcus aureus agr and sarA functions are required for
invasive infection but not inflammatory responses in the lung. Infect Immun,
2002. 70(1): p. 127-133.

120.

Parker, D. and A. Prince, Immunopathogenesis of Staphylococcus aureus
pulmonary infection. Semin Immunopathol, 2012. 34(2): p. 281-97.

121.

Thoendel, M., et al., Peptide signaling in the staphylococci. Chem Rev, 2011.
111(1): p. 117-51.

122.

Cheung, G.Y., et al., Role of the accessory gene regulator agr in communityassociated methicillin-resistant Staphylococcus aureus pathogenesis. Infect
Immun, 2011. 79(5): p. 1927-35.

123.

Hall, P.R., et al., Nox2 Modification of LDL Is Essential for Optimal
Apolipoprotein B-mediated Control of agr Type III Staphylococcus aureus
Quorum-sensing. Plos Pathogens, 2013. 9(2).

124.

Harris, H.W., et al., Human very low density lipoproteins and chylomicrons can
protect against endotoxin-induced death in mice. J Clin Invest, 1990. 86(3): p.
696-702.

125.

Read, T.E., et al., The protective effect of serum lipoproteins against bacterial
lipopolysaccharide. Eur Heart J, 1993. 14 Suppl K: p. 125-129.

126.

Sigel, S., et al., Apolipoprotein B100 is a suppressor of Staphylococcus aureusinduced innate immune responses in humans and mice. Eur J Immunol, 2012.
42(11): p. 2983-2989.
84

127.

Rothfork, J.M., et al., Inactivation of a bacterial virulence pheromone by
phagocyte-derived oxidants: new role for the NADPH oxidase in host defense.
Proc Natl Acad Sci U S A, 2004. 101(38): p. 13867-72.

128.

Bernheimer, A.W., Assay of hemolytic toxins. Methods Enzymol, 1988.
165(0076-6879): p. 213-7.

129.

Sully, E.K., et al., Selective chemical inhibition of agr quorum sensing in
Staphylococcus aureus promotes host defense with minimal impact on resistance.
PLoS Pathog, 2014. 10(6): p. e1004174.

130.

Farese, R.V., Jr., et al., Knockout of the mouse apolipoprotein B gene results in
embryonic lethality in homozygotes and protection against diet-induced
hypercholesterolemia in heterozygotes. Proc Natl Acad Sci U S A, 1995. 92(5): p.
1774-8.

131.

Mounkes, L.C., et al., Evaluation of the role of lipoprotein metabolism genes in
systemic cationic liposome-mediated gene transfer in vivo. Hum Gene Ther, 2001.
12(1043-0342; 16): p. 1939-1954.

132.

Rashid, S., et al., Decreased plasma cholesterol and hypersensitivity to statins in
mice lacking Pcsk9. Proc Natl Acad Sci U S A, 2005. 102(0027-8424; 15): p.
5374-5379.

133.

Malone, C.L., et al., Fluorescent reporters for Staphylococcus aureus. J
Microbiol Methods, 2009. 77(3): p. 251-60.

134.

Chaffin, D.O., et al., Changes in the Staphylococcus aureus transcriptome during
early adaptation to the lung. PLoS One, 2012. 7(8): p. e41329.

135.

Ragle, B.E. and J.B. Wardenburg, Anti-alpha-hemolysin monoclonal antibodies
mediate protection against Staphylococcus aureus pneumonia. Infect Immun,
2009. 77(7): p. 2712-2718.

136.

Bubeck Wardenburg, J., W.A. Williams, and D. Missiakas, Host defenses against
Staphylococcus aureus infection require recognition of bacterial lipoproteins.
Proc Natl Acad Sci U S A, 2006. 103(37): p. 13831-13836.

137.

Bartlett, A.H., et al., Alpha-toxin facilitates the generation of CXC chemokine
gradients and stimulates neutrophil homing in Staphylococcus aureus pneumonia.
J Infect Dis, 2008. 198(10): p. 1529-1535.

138.

Rigby, K.M. and F.R. DeLeo, Neutrophils in innate host defense against
Staphylococcus aureus infections. Semin Immunopathol, 2012. 34(2): p. 237-59.

85

139.

Grommes, J. and O. Soehnlein, Contribution of neutrophils to acute lung injury.
Mol Med, 2011. 17(3-4): p. 293-307.

140.

Rose, F., et al., Mediator generation and signaling events in alveolar epithelial
cells attacked by S. aureus alpha-toxin. Am J Physiol Lung Cell Mol Physiol,
2002. 282(2): p. L207-14.

141.

Bhakdi, S., et al., Binding and partial inactivation of Staphylococcus aureus
alpha-toxin by human plasma low density lipoprotein. J Biol Chem, 1983. 258(9):
p. 5899-5904.

142.

Feingold, K.R., et al., Role for circulating lipoproteins in protection from
endotoxin toxicity. Infect Immun, 1995. 63(5): p. 2041-6.

143.

Oku, Y., et al., Pleiotropic roles of polyglycerolphosphate synthase of lipoteichoic
acid in growth of Staphylococcus aureus cells. J Bacteriol, 2009. 191(1): p. 14151.

144.

Fedtke, I., et al., A Staphylococcus aureus ypfP mutant with strongly reduced
lipoteichoic acid (LTA) content: LTA governs bacterial surface properties and
autolysin activity. Mol Microbiol, 2007. 65(4): p. 1078-91.

145.

Wang, R., et al., Identification of novel cytolytic peptides as key virulence
determinants for community-associated MRSA. Nat Med, 2007. 13(12): p. 15101514.

146.

Queck, S.Y., et al., RNAIII-Independent Target Gene Control by the agr QuorumSensing System: Insight into the Evolution of Virulence Regulation in
Staphylococcus aureus. Mol Cell, 2008. 32(1): p. 150-158.

147.

Leonenko, Z., et al., An elevated level of cholesterol impairs self-assembly of
pulmonary surfactant into a functional film. Biophys J, 2007. 93(2): p. 674-83.

148.

Nahak, P., et al., Effect of serum, cholesterol and low density lipoprotein on the
functionality and structure of lung surfactant films. J Oleo Sci, 2014. 63(12): p.
1333-49.

149.

Ariki, S., C. Nishitani, and Y. Kuroki, Diverse functions of pulmonary collectins
in host defense of the lung. J Biomed Biotechnol, 2012. 2012: p. 532071.

150.

McCormack, F.X. and J.A. Whitsett, The pulmonary collectins, SP-A and SP-D,
orchestrate innate immunity in the lung. J Clin Invest, 2002. 109(6): p. 707-12.

151.

Hartshorn, K.L., et al., Pulmonary surfactant proteins A and D enhance
neutrophil uptake of bacteria. Am J Physiol, 1998. 274(6 Pt 1): p. L958-69.

86

152.

Sever-Chroneos, Z., et al., Surfactant protein A (SP-A)-mediated clearance of
Staphylococcus aureus involves binding of SP-A to the staphylococcal adhesin
eap and the macrophage receptors SP-A receptor 210 and scavenger receptor
class A. J Biol Chem, 2011. 286(6): p. 4854-70.

153.

Kantyka, T., et al., Staphylococcus aureus proteases degrade lung surfactant
protein A potentially impairing innate immunity of the lung. J Innate Immun,
2013. 5(3): p. 251-60.

154.

Hass, M.A. and W.J. Longmore, Regulation of lung surfactant cholesterol
metabolism by serum lipopoteins. Lipids, 1980. 15(6): p. 401-6.

155.

Karadag, A., et al., Pathological case of the month. Celiac disease with
acanthocytosis. Arch Pediatr Adolesc Med, 2002. 156(3): p. 291-2.

156.

Shah, S.S. and H.G. Desai, Apolipoprotein deficiency and chronic liver disease. J
Assoc Physicians India, 2001. 49: p. 274-8.

157.

Ruiz-Sandoval, J.L., C. Cantu, and F. Barinagarrementeria, Intracerebral
hemorrhage in young people: analysis of risk factors, location, causes, and
prognosis. Stroke, 1999. 30(3): p. 537-41.

158.

Iso, H., et al., Serum cholesterol levels and six-year mortality from stroke in
350,977 men screened for the multiple risk factor intervention trial. N Engl J
Med, 1989. 320(14): p. 904-10.

159.

Vermont, C.L., et al., Serum lipids and disease severity in children with severe
meningococcal sepsis. Crit Care Med, 2005. 33(7): p. 1610-5.

160.

Elissalde, G.S., et al., Hypocholesterolemia and hypocortisolemia in acute and
terminal Babesia bovis infections. Vet Parasitol, 1983. 12(1): p. 1-11.

161.

Marik, P.E., Dyslipidemia in the critically ill. Crit Care Clin, 2006. 22(1): p. 1519, viii.

162.

Gehr, P., et al., Airway surfactant, a primary defense barrier: mechanical and
immunological aspects. J Aerosol Med, 1996. 9(2): p. 163-81.

163.

van Iwaarden, F., et al., Pulmonary surfactant protein A enhances the hostdefense mechanism of rat alveolar macrophages. Am J Respir Cell Mol Biol,
1990. 2(1): p. 91-8.

164.

Tino, M.J. and J.R. Wright, Surfactant protein A stimulates phagocytosis of
specific pulmonary pathogens by alveolar macrophages. Am J Physiol, 1996.
270(4 Pt 1): p. L677-88.

87

165.

Manz-Keinke, H., H. Plattner, and J. Schlepper-Schafer, Lung surfactant protein
A (SP-A) enhances serum-independent phagocytosis of bacteria by alveolar
macrophages. Eur J Cell Biol, 1992. 57(1): p. 95-100.

166.

Haagsman, H.P., et al., Surfactant collectins and innate immunity. Neonatology,
2008. 93(4): p. 288-94.

167.

Kingma, P.S. and J.A. Whitsett, In defense of the lung: surfactant protein A and
surfactant protein D. Curr Opin Pharmacol, 2006. 6(3): p. 277-83.

168.

Alcorn, J.F. and J.R. Wright, Degradation of pulmonary surfactant protein D by
Pseudomonas aeruginosa elastase abrogates innate immune function. J Biol
Chem, 2004. 279(29): p. 30871-9.

169.

Ikegami, M., A. Jobe, and D. Berry, A protein that inhibits surfactant in
respiratory distress syndrome. Biol Neonate, 1986. 50(3): p. 121-9.

170.

Holm, B.A., G. Enhorning, and R.H. Notter, A biophysical mechanism by which
plasma proteins inhibit lung surfactant activity. Chem Phys Lipids, 1988. 49(1-2):
p. 49-55.

171.

Cockshutt, A.M., J. Weitz, and F. Possmayer, Pulmonary surfactant-associated
protein A enhances the surface activity of lipid extract surfactant and reverses
inhibition by blood proteins in vitro. Biochemistry, 1990. 29(36): p. 8424-9.

172.

Wang, D., et al., A pure population of lung alveolar epithelial type II cells derived
from human embryonic stem cells. Proc Natl Acad Sci U S A, 2007. 104(11): p.
4449-54.

173.

Steinberg, D., The LDL modification hypothesis of atherogenesis: an update. J
Lipid Res, 2009. 50 Suppl: p. S376-81.

174.

Han, J., et al., Native and modified low density lipoproteins increase the
functional expression of the macrophage class B scavenger receptor, CD36. J
Biol Chem, 1997. 272(34): p. 21654-9.

175.

Lara, L.L., et al., Low density lipoprotein receptor expression and function in
human polymorphonuclear leucocytes. Clin Exp Immunol, 1997. 107(1): p. 20512.

176.

Memon, R.A., et al., Infection and inflammation induce LDL oxidation in vivo.
Arterioscler Thromb Vasc Biol, 2000. 20(6): p. 1536-42.

177.

Malle, E., et al., Modification of low-density lipoprotein by myeloperoxidasederived oxidants and reagent hypochlorous acid. Biochim Biophys Acta, 2006.
1761(4): p. 392-415.
88

178.

De Nardo, D., et al., High-density lipoprotein mediates anti-inflammatory
reprogramming of macrophages via the transcriptional regulator ATF3. Nat
Immunol, 2014. 15(2): p. 152-60.

179.

Murphy, A.J., et al., Neutrophil activation is attenuated by high-density
lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation.
Arterioscler Thromb Vasc Biol, 2011. 31(6): p. 1333-41.

180.

Kopprasch, S., J. Pietzsch, and J. Graessler, The protective effects of HDL and its
constituents against neutrophil respiratory burst activation by hypochloriteoxidized LDL. Mol Cell Biochem, 2004. 258(1-2): p. 121-7.

181.

Palanisamy, G.S., et al., Uptake and accumulation of oxidized low-density
lipoprotein during Mycobacterium tuberculosis infection in guinea pigs. PLoS
One, 2012. 7(3): p. e34148.

182.

Zhu, X., et al., Myeloid cell-specific ABCA1 deletion protects mice from bacterial
infection. Circ Res, 2012. 111(11): p. 1398-409.

183.

Warnatsch, A., et al., Inflammation. Neutrophil extracellular traps license
macrophages for cytokine production in atherosclerosis. Science, 2015.
349(6245): p. 316-20.

184.

Chou, M.Y., et al., Oxidation-specific epitopes are important targets of innate
immunity. J Intern Med, 2008. 263(5): p. 479-88.

185.

Hebert, P.R., et al., Cholesterol lowering with statin drugs, risk of stroke, and
total mortality. An overview of randomized trials. JAMA, 1997. 278(4): p. 31321.

186.

Gotto, A.M., Jr., Cholesterol management in theory and practice. Circulation,
1997. 96(12): p. 4424-30.

187.

O'Neal, H.R., Jr., et al., Prehospital statin and aspirin use and the prevalence of
severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care
Med, 2011. 39(6): p. 1343-50.

188.

Yende, S., et al., Understanding the potential role of statins in pneumonia and
sepsis. Crit Care Med, 2011. 39(8): p. 1871-8.

189.

Horn, M.P., et al., Simvastatin inhibits Staphylococcus aureus host cell invasion
through modulation of isoprenoid intermediates. J Pharmacol Exp Ther, 2008.
326(1): p. 135-43.

89

190.

Wu, B.Q., et al., Inhibitory effects of simvastatin on staphylococcus aureus
lipoteichoic acid-induced inflammation in human alveolar macrophages. Clin
Exp Med, 2014. 14(2): p. 151-60.

191.

Chow, O.A., et al., Statins enhance formation of phagocyte extracellular traps.
Cell Host Microbe, 2010. 8(5): p. 445-54.

192.

Statt, S., et al., Statins Enhance Cellular Resistance Against Bacterial Poreforming Toxins in Airway Epithelial Cells. Am J Respir Cell Mol Biol, 2015.

90

